

AD _____

Award Number: DAMD17-98-1-8109

TITLE: Chemomodulation of Doxorubicin Pharmacodynamics

PRINCIPAL INVESTIGATOR: Rajagopalan Sridhar, Ph.D.

CONTRACTING ORGANIZATION: Howard University
Washington, DC 20059

REPORT DATE: July 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050105 018

BEST AVAILABLE COPY

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| | | | | |
|--|---|--|--|----------------------------------|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE July 2004 | 3. REPORT TYPE AND DATES COVERED Final (30 Sep 98-29 Jun 04) | |
| 4. TITLE AND SUBTITLE Chemomodulation of Doxorubicin Pharmacodynamics | | | 5. FUNDING NUMBERS DAMD17-98-1-8109 | |
| 6. AUTHOR(S) Rajagopalan Sridhar, Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Howard University Washington, DC 20059 e-mail: rsidhar@Howard.edu | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | 12b. DISTRIBUTION CODE |
| 13. ABSTRACT (Maximum 200 Words) <p>The project aims to develop strategies for using doxorubicin in the treatment of multidrug resistant advanced breast cancer while simultaneously minimizing the risk of cardiotoxicity. The wild type MCF-7 breast cancer cells and the multidrug resistant cell line designated as MCF7/ADR were genetically unrelated. This slowed the progress of our research. However, genetically related MCF-7 wild type and its genetically related multidrug resistant variant were acquired and used successfully in our studies. We have found that in general, multidrug resistance reversing agents inhibit free radical mediated microsomal lipid peroxidation, but do not inhibit the conversion of doxorubicin to its semiquinone free radical. Several potent multidrug reversing agents have been identified. Several antiestrogens including tamoxifen sensitized drug resistant breast cancer cells to cytotoxicity of doxorubicin. The natural product tetrandrine and the anti diarrhea medicine loperamide were potent agents for reversing multidrug resistance. Both dipyrindamole and raloxifene resembled tamoxifen in potentiating the cytotoxicity of doxorubicin towards MCF7/ADR cells, and inhibiting doxorubicin mediated microsomal lipid peroxidation. Raloxifene, dipyrindamole and tamoxifen can inhibit protein kinase C, which is an attractive target for modulating multidrug resistance. Nicotine, which is cardiotoxic, can activate protein kinase C pathway. Raloxifene, tamoxifen and dipyrindamole have basic amino groups in common, but unlike nicotine, they inhibit protein kinase C and sensitize multidrug resistant cells.</p> | | | | |
| 14. SUBJECT TERMS Breast Cancer | | | | 15. NUMBER OF PAGES 88 |
| | | | | 16. PRICE CODE |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

| | |
|--|-------|
| Cover..... | 1 |
| SF 298..... | 2 |
| Table of Contents..... | 3 |
| Introduction..... | 4 |
| Body..... | 5-8 |
| Key Research Accomplishments..... | 8-9 |
| Reportable Outcomes..... | 9-14 |
| Conclusions..... | 14-15 |
| References..... | 16-18 |
| Appendices List..... | 19-20 |
| Appendices #1 to # 28 (pages not numbered) | 21-88 |

INTRODUCTION

The anti-cancer drug doxorubicin (adriamycin) causes severe adverse effects at high doses and loses its efficacy against multidrug resistant tumors including breast cancer. Potentially fatal cardiotoxicity can develop in patients when the cumulative dose of the drug exceeds 450 mg/m^2 . For optimum use of doxorubicin it is necessary to overcome multidrug resistance of tumor with simultaneous protection against cardiotoxicity. Cardiotoxicity may result from the tendency of doxorubicin and its metabolites to accumulate in the heart and trigger free radical mediated injury (1-3). At present, R-verapamil, tamoxifen, raloxifene, toremifene and dipyridamole are being considered as chemosensitizers for reversing tumor resistance to doxorubicin. It is important to identify and avoid conditions under which they preferentially sensitize the tumor without subjecting the heart to the deleterious effects. Free radicals are known to induce apoptosis. If free radicals are the cause of cardiotoxicity, then R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole should protect the heart by virtue of their anti-peroxidant action. If apoptosis is the cause of cardiac injury then the alleged anti-apoptotic action of these chemicals should be beneficial to the heart. If cardiotoxicity is the result of altered kinetics and metabolism of doxorubicin to the more toxic doxorubicinol, then certain metabolic inhibitors would afford protection. Apoptosis in the tumor is desirable, whereas apoptosis in the heart is detrimental. Methods for decreasing the free radical burden in the heart and preventing the accumulation of doxorubicin and its metabolites in the heart may improve the clinical usefulness of doxorubicin. This may be achievable because the antitumor action of doxorubicin may occur through inhibition of DNA topoisomerase with minimal involvement of free radicals. The mechanisms involved in the actions of these pharmacologically diverse compounds may hold valuable clues for improved cancer therapy and protection against cardiotoxicity. The specific aims of the project are:

#1: To determine if R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole alter the metabolic and pharmacokinetic profiles of doxorubicin in athymic nude mice with multidrug resistant MCF-7 human tumor xenografts. High pressure liquid chromatography (HPLC) will be utilized to measure the concentration of doxorubicin, doxorubicinol and the chemomodulator in blood, tumor, heart, kidneys and liver of mice. The extent of lipid peroxidation and the concentration of reduced glutathione will be determined in heart and liver tissue by standard biochemical assays.

#2: To determine if R-verapamil, tamoxifen, toremifene, raloxifene and dipyridamole have differential effects on programmed cell death (apoptosis) in cardiac tissue compared to the tumor. The extent of apoptosis in heart tissue and tumor will be assayed *in situ* by histological methods and by DNA laddering assays in order to correlate cardiac damage with extent of apoptosis.

#3: To apply the electron spin resonance (ESR) technique of spin trapping to compare the influence of R- and S-verapamil on doxorubicin-induced free radical formation *in vitro* and *in vivo*. Alpha-(2,4,6-trimethoxyphenyl) N-tert-butyl nitron (TMeOPBN) will be administered to mice for *in vivo* studies and TMeOPBN and 5,5-dimethylpyrroline N-oxide (DMPO) will be used for *in vitro* experiments with cardiac microsomes and mitochondria isolated from animals in the different treatment groups. The long term goal is to find safer methods of treating multidrug resistant advanced breast cancer with doxorubicin while preventing cardiotoxic side effects of treatment.

BODY

There are several reports that the MCF-7/ADR cell line used at many research centers for investigating doxorubicin resistance in human breast tumor cells is not genetically related to its presumed parental cell line MCF-7 (4-6). Multidrug resistant breast cancer cell lines whose pedigree can be reliably traced to their parental cell lines have been obtained by researchers in other laboratories by transfection of the appropriate genes for drug resistance. Matched sensitive (wild type) and its multidrug resistant variant are now available to us from reliable sources such as Georgetown University and the National Cancer Institute. We have to repeat many of the experiments that were carried out earlier with MCF-7/ADR, using these matched pairs of breast cancer cell lines of varying drug sensitivities. Our attempts to produce multidrug resistant MCF-7 cells by serial exposures to graded concentrations of doxorubicin failed to yield stable drug resistant mutants. Therefore we have depended on the cell lines developed in Georgetown University by Dr. Robert Clarke (specifically MDA 435/LCC6 and its multidrug resistant derivative MDA 435/LCC6MR1) and by Dr. Michael Gottesman of the National Cancer Institute, National Institutes for Health (MCF-7 and MCF-7 MDR clone 10.3, which has been transduced with MDR1).

The HPLC techniques have been developed and the necessary quality control measures have been established. These will be directly applicable to pharmacokinetic studies. A standard curve was generated for quantitative analysis of doxorubicin using daunomycin as an internal standard (Appendix 1). The reproducibility of the method was also tested (Table 1 and Table 2 in Appendix 2)

Flow cytometry was used to characterize the cell lines with respect to the presence of the protein associated with multidrug resistance. As expected, the protein associated with multidrug resistance was found only in MCF-7/ADR cells but not in wild type MCF-7 human breast cancer cells.

Since multidrug resistance is associated with an ATP binding permeability glycoprotein (pgp 170), the influence of glucose on the growth of the two cell lines was examined. The two cells differed in their response to high levels of glucose (Appendix 3). Increasing the glucose concentration in the medium from 5 mM to 25 mM was without effect on MCF-7/ADR cells, but stimulated further growth of MCF-7 cells. This may have some bearing on the growth and progression of tumors in diabetic individuals.

The cell lines were further characterized in terms of their sensitivity to doxorubicin in the presence and absence of tamoxifen (Appendix 4-8). Isobologram analysis revealed synergistic interaction of doxorubicin with tamoxifen in the case of MCF-7/ADR but not MCF-7 cells (Appendix 7 and 8).

Electron spin resonance (ESR) techniques were utilized to study free radical production in cells treated with doxorubicin. The formation of semiquinone free radical from doxorubicin was detected in anaerobic incubations of cells (Appendix 9). The spin trap DMPO was utilized to detect the formation of hydroxyl free radicals by cells incubated with doxorubicin and DMPO under aerobic conditions (Appendix 10). The dose of doxorubicin needed for demonstrating free

radical production was quite cytotoxic and comparison of the results from the drug sensitive MCF-7 and the drug resistant MCF-7/ADR cells was further complicated by the differences in tolerance to doxorubicin.

The ability of tamoxifen to inhibit microsomal lipid peroxidation was studied using liver and cardiac microsomes (Appendix 11-12). The concentration dependent effect of doxorubicin on microsomal lipid peroxidation was studied (Appendix 13).

The *in vivo* studies associated with task 3 (pharmacokinetic analysis and apoptosis assays in animals) of statement of work have been delayed. However, we have grown MCF-7/ADR cells as solid tumor xenografts in nude mice as part of another ongoing project dealing with *in vivo* phosphorus nuclear magnetic resonance spectroscopy. We will soon initiate tumor transplantation for pharmacokinetic studies and apoptosis assays using authentic multidrug resistant breast cancer cells. A prior assessment of the factors influencing apoptosis will be useful for interpreting the results of apoptosis assays on tissue and tumor samples from treated animals. Therefore the effects of different agents on doxorubicin-mediated apoptosis were studied.

Inhibitors of protein kinase C are known to play a regulatory role in cell proliferation and apoptosis. Protein kinases have been identified as therapeutic targets that are worth exploring (7). Tamoxifen, raloxifene and dipyridamole are inhibitors of protein kinase C, which is being recognized as an attractive target in cancer chemotherapy, especially for overcoming multidrug resistance (7-9). The influence of oxidative stress, pH and calcium homeostasis in drug resistance is being actively studied in several laboratories (10-13).

The multidrug resistance reversing agents, tamoxifen, dipyridamole, verapamil and raloxifene are inhibitors of protein kinase C. Furthermore, these compounds possess some antiperoxidant activity and a tendency to perturb calcium homeostasis in cells. The basic amino groups in compounds such as nicotine, tamoxifen and dipyridamole, can alter intracellular pH and influence cellular uptake of anticancer drugs. The diverse pharmacological properties make *in vivo* study of these compounds exciting. *In vitro* experiments have been carried out as preparation for the projected *in vivo* studies on tumor bearing mice.

Necrosis was the major source of cell death in doxorubicin treated MCF-7/ADR cells. These cells are probably not of breast origin in spite of the nomenclature used. These cells have mutated p53, which may account for their resistance to apoptosis (4,14) (Appendix 14).

The protein kinase C inhibitors tamoxifen, raloxifene and dipyridamole partially sensitized MCF-7/ADR cells to doxorubicin, when cell viability was estimated using colony formation assays. These compounds also inhibited doxorubicin stimulated microsomal lipid peroxidation. All three compounds displayed non protein thiol sparing effect in microsomes treated with doxorubicin. This confirms the anti-oxidant properties of these compounds.

Nicotine, tamoxifen, raloxifene and dipyridamole are amino compounds with some basic character. Nicotine activates protein kinase pathways in some cellular systems (15-19). This is in contrast to the other three compounds which inhibit protein kinase C. Interestingly, nicotine

decreased the cytotoxicity of doxorubicin towards MCF-7 cells (Appendix 14 and 22) (14).

Adenosine triphosphate (ATP) is needed for pathways leading to apoptosis, and ATP depletion promotes necrosis (Appendix 15) (20). Therefore it is important to understand the effects of different pharmacological agents on cellular energy production. In collaboration with Dr. Paul Wang of our University, we have utilized ^{31}P NMR spectroscopy to study ATP producing capacity of MCF-7/ADR cells (21). The technique should allow us to compare the effects of tamoxifen and doxorubicin on ATP production and glucose utilization by drug sensitive and resistant cells. We had noted differences in the glucose mediated proliferative responses of MCF-7 and MCF-7/ADR cells (22). Since these cell lines are genetically unrelated, we will repeat the experiments with authentic genetically related pairs of drug sensitive and drug resistant breast cancer cell lines.

The importance of the sphingomyelinase - ceramide pathway in ceramide mediated apoptosis and drug resistance is rapidly gaining recognition (Appendix 16). The roles of sphingomyelin and ceramide pathways in multidrug tumor cell sensitivity and resistance are being examined in several laboratories (23-29). We are teaming up with Dr. Xinbin Gu of our University, to investigate the effect of nitron spin traps and nitroxyl spin labels on ceramide mediated apoptosis. Free radical initiated apoptosis can be triggered via sphingomyelinase pathway. Nitrones and nitroxyls exhibit antiperoxidant activity in systems where dipyrindamole and tamoxifen also inhibit peroxidation. Therefore, we will compare the abilities of these compounds to perturb the sphingomyelinase pathway and apoptosis in drug sensitive and resistant breast cancer cells treated with and without doxorubicin.

Important differences were noted in the metabolic activation of doxorubicin and another anthracycline, mitoxantrone (Appendix 17). Mitoxantrone yielded free radical intermediates during oxidative as well as reductive metabolism. Free radicals were detectable by electron spin resonance techniques only during reductive metabolism of doxorubicin (30).

We also observed that the neutral red assay for cell viability was unreliable when used with multidrug resistant cells, presumably due to lack of adequate retention of the dye by the drug resistant cells (Appendix 18 and 23). This assay also overestimated the viability of heat inactivated cancer cells (31).

Among several compounds tested, loperamide, an over the counter medicine for treatment of diarrheah was a potent sensitizer of multidrug resistant MCF 7 clone 10.3 cells towards doxorubicin. (Appendix 25). Flow cytometry measurements indicated that loperamide increased the accumulation of doxorubicin in these drug resistant cells.

We evaluated a series of 1,1-dichloro-2,3-di- and tri-aryl cyclopropanes as multi drug resistance reversing agents. Many of these act as pure anti-estrogens. This is in contrast with tamoxifen which has some estrogenic activity in addition to its well documented anti-estrogenic features. Some of these antiestrogens were nearly as effective as tamoxifen in overcoming cellular resistance to doxorubicin. (32). (Appendix 26).

In view of the recent interest in natural products as therapeutic agents, we tested tetrandrine and berberine, which are used in traditional Chinese medicine, as sensitizers of multidrug resistant

MCF 7 clone 10.3 cells towards doxorubicin. (Appendix 27).

We had several setbacks associated with misidentification of the MDR cell line. The cell line that was originally obtained was probably a drug resistant cancer line unrelated to breast. The current resistant cell line MCF-7 clone 10.3 is an authentic multidrug resistant breast cancer, which is easily passaged both in vitro and in vivo as solid tumor xenografts in Balb/c nude mice.

We have started preparing manuscripts on all our results (task 4: statement of work), and expect to submit them for consideration of publication in peer reviewed journals.

KEY RESEARCH ACCOMPLISHMENTS

- HPLC method for measuring doxorubicin content in biological samples has been standardized.
- MCF-7 and MCF-7/ADR cells have differ in their growth patterns in RPMI medium with normal (5 mM) and high (25 mM) glucose levels.
- MCF-7 and MCF-7/ADR cells metabolize doxorubicin to the corresponding semiquinone free radical. However, the concentration of doxorubicin used to demonstrate this results in reproductive cell death of the cells. The semiquinone free radical was observed under anaerobic conditions. Including 5,5-dimethylpyrroline-N-oxide (DMPO) as a spin trap enabled the detection of hydroxyl radical in aerobic incubation mixtures.
- Tamoxifen inhibited doxorubicin stimulated lipid peroxidation in both liver and cardiac microsomes.
- Tamoxifen by itself causes reproductive cell death. Tamoxifen interacts synergistically with doxorubicin to cause reproductive cell death in MCF-7/ADR cells, but the interaction is only additive in the case of wild type MCF-7 cells.
- Demonstrated necrosis to be the major cause of cell death in doxorubicin-treated MCF-7/ADR cells.
- Demonstrated the PKC inhibitors tamoxifen, raloxifene, and dipyridamole partially sensitized MCF-7/ADR cells to doxorubicin when cell viability was estimated using colony formation assays.
- Demonstrated that nicotine activates PKC pathways in some cellular systems in contrast to the other three compounds that inhibit PKC.
- Utilized ³¹PNMR spectroscopy to distinguish drug sensitive and multidrug resistant cells.
- Nitrones and nitroxyls can perturb the sphingomyelinase pathway and apoptosis in drug-sensitive and -resistant cells treated with and without doxorubicin.
- Detected free radicals during reductive metabolism of doxorubicin and mitoxantrone.
- Observed that neutral red assay for cell viability was unreliable when used with MDR cells, and overestimated the viability of heat inactivated cancer cells.
- Doxorubicin lethality after multiple dosing with LD₁₀ is associated with bone marrow depletion.
- Doxorubicin treatment (LD₁₀) of mice decreased cardiac levels of non protein sulfhydryl by nearly 50 percent whereas the levels of total sulfhydryl and protein bound sulfhydryl

were not significantly affected.

- An EPR method for measuring the sulfhydryl levels in cells was utilized successfully.
- The different MDR reversing agents did not affect the conversion of doxorubicin to the corresponding semiquinone under anaerobic conditions.
- Microsomal metabolism of doxorubicin is inhibited by tamoxifen
- Agents that reverse multidrug resistance inhibit microsomal lipid peroxidation.
- Natural products such as terandrine and berberine modified the sensitivity of multidrug resistant breast cancer cells to doxorubicin by inhibiting the expression of *mdr* gene.
- A series of synthetic antiestrogens were found to reverse multidrug resistance of breast cancer cells in culture.
- Have demonstrated that the anti-diarrheal agent loperamide is extremely effective in overcoming multidrug resistance of human breast cancer cells.
- Inhibitors of P-gp causes enhanced retention of drugs in the heart and brain.

REPORTABLE OUTCOMES:

Manuscripts

Sridhar, R., Hanson-Painton, O. and Cooper, D.R. 2000. Protein kinases as therapeutic targets. *Pharmaceut. Res.* 17: 1345-1353, 2000.

Oredipe, O.A., Furbert-Harris, P.M., Laniyan, I., Green, W.R., Griffin, W.M. and Sridhar, R. Coadministration of swainsonine and doxorubicin attenuates doxorubicin-induced lethality in mice. *Cell. Mol. Biol.* 49: 1037-1048, 2003.

Oredipe, O.A., Furbert-Harris, P.M., Laniyan, I., Green, W.R., Griffin, W.M. and Sridhar, R. Mice primed with swainsonine are protected against doxorubicin-induced lethality. *Cell. Mol. Biol.* 49: 1089-1099, 2003.

Abstracts

Zhou, Y., and Sridhar, R. Interaction of tamoxifen with doxorubicin. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume II, June 8-11, 2000, Atlanta, GA, pp 684.

Wang, P.C., Liu, D., Agwu, E. and Sridhar, R. Application of P31 NMR spectroscopy to distinguish drug sensitive and drug resistant breast cancer. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, June 8-11, 2000, Atlanta, GA, pp 217.

Sridhar, R., and Desai, P.B. Similarities and differences in mechanisms of free radical formation from mitoxantrone and doxorubicin. Abstract presented at the Annual Meeting of American Association for Cancer Research, New Orleans, LA. 2001. *Proc. Amer. Assoc. cancer Res.* 42: 935, 2001 (Abstract #5017).

Sridhar, R., Balan, K.B., Shankar, R.A., Zhou, Y. and Goldson, A.L. Observations on the application of neutral red assay for cell viability. Abstract of presentation at EXPERIMENTAL BIOLOGY 2001, Orlando, FL, 2001. FASEB J. 15 (4): pp A238, 2001.

Wang, P.C., Zhou, J., Agwu, C.E., Li, E. and Sridhar, R. An improved perfusion system for NMR study of breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume III, Abstract P40-30, September 25-28, 2002, Orlando, FL

Zhou, Y., Gu, X., Dhingra, S. and Sridhar, R. 2002. Nicotine inhibits doxorubicin -induced apoptosis of human breast cancer cells in culture. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, Abstract P10-25, September 25-28, 2002, Orlando, FL

Zhou, Y., Sridhar, R., Gu, X., Pang, X., Balachandran, R., Magarian, R.A. and Day, B.W. Evaluation of a series of 1,1-dichloro-2,3-di- and tri-arylcyclopropanes as MDR reversing agents. Proc. Amer. Assoc. Cancer Res. 45: 2004, Abstract # 2139.

Ally, N., Zhou, Y., Zhang, R. and Sridhar, R. Chemomodulation of multidrug resistance of human breast cancer cells. Abstract of paper presented at the Fifteenth Annual Howard University Medical Center, Resident/Faculty Scientific Forum: May 5, 2004.

Publications since 1998 (also includes articles unrelated to the grant)

Kapadia, G.J., Tokuda, H. Sridhar, R., Balasubramanian, V., Takayasu, J., Bu, P., Takasaki, M., Konoshima, T., Nishino, H. Cancer chemopreventive activity of synthetic colorants used in foods, pharmaceuticals and cosmetic preparations. Cancer Letters 129: 87-95, 1998.

Jackson, M.M., Hou, L.H., Banerjee, H.N., Sridhar, R. and Dutta, S.K. Disappearance of 2,4-dinitrotoluene and 2-amino,4,6-dinitrotoluene by *Phanerochaete chrysosporium* under non ligninolytic conditions. Bull. Environ. Contamin. Toxicol. 62: 390-396, 1999.

Yamamoto, M., Patel, N., Taggert, J., Sridhar, R. and Cooper, D.R. A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells which overproduce PKC- β II. Int. J. Cancer 83: 98-106, 1999.

Krishnamurthy, R., Lumpkin, J. and Sridhar, R. Inactivation of lysozyme by sonication under conditions relevant to microencapsulation. Int. J. Pharmaceutics 205: 23-34, 2000.

Karkera, J.D., Ayache, S., Ransome, Jr., R.J., Jackson, M.A., Elsayem, A.F., Sridhar, R., Detera-Wadleigh, S. and Wadleigh, R.G. Refinement of regions with allelic loss on chromosome 18p11.2 and 18q12.2 in esophageal squamous cell carcinoma. Clin. Cancer Res. 6: 3565-3569, 2000.

Sridhar, R., Hanson-Painton, O. and Cooper, D.R. Protein kinases as therapeutic targets. *Pharmaceut. Res.* 17: 1345-1353, 2000.

Cooper, D.R., Hanson-Painton, O. and Sridhar, R. Protein kinases and disease. In *Calbiochem Signal Transduction Catalog & technical Resource* 2001 pp 283-285

Kapadia, G.J., Azuine, M.A., Balasubramanian, V. and Sridhar, R. Aminonaphthaquinones - A novel class of compounds with potent antimalarial activity against *Plasmodium falciparum*. *Pharmacological Res.* 43: 363-367, 2001.

Kapadia, G.J., Azuine, M.A., Tokuda, H., Hang, E., Mukainaka, T., Nishino, H. and Sridhar, R. Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted epstein-barr virus early antigen activation. *Pharmacol. Res.* 45: 213-220, 2002.

Ashayeri, E., Omogbehin, A., Sridhar, R. and Shankar, R.A. Strontium 89 in the treatment of pain due to diffuse osseous metastases : a university hospital experience. *J. Natl. Med. Assoc.* 94: 706-711, 2002.

Oredipe, O.A., Furbert-Harris, P.M., Green, W.R., White, S.L., Olden, K., Laniyan, I., Parish-Gause, D., Vaughn, T., Griffin, W.M. and Sridhar, R. Swainsonine stimulates bone marrow cell proliferation and differentiation in different strains of inbred mice. *Pharmacol. Res.* 47: 69-74, 2003.

Kapadia, G.J., Auine, M.A., Sridhar, R., Okuda, Y., Tsuruta, A., Ichiishi, E., Mukainake, T., Takasaki, M., Konoshima, T., Nishino, H. and Tokuda, H. Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beet root. *Pharmacol. Res.* 47: 141-148, 2003.

Oredipe, O.A., Furbert-Harris, P.M., Green, W.R., White, S.L., Olden, K., Laniyan, I., Parish-Gause, D., Vaughn, T., Griffin, W.M. and Sridhar, R. Enhanced proliferation of functionally competent bone marrow cells in different strains of mice treated with swainsonine. *Int. Immunopharmacol.* 462: 1-11, 2003.

Cooper, D.R., Hanson-Painton, O. and Sridhar, R. Protein kinases and disease. In "Calbiochem Signal Transduction Catalog & Technical Resource", 2003/04, pp 345-348.

Shankar, R.A., Nibhanupudy, J.R., Sridhar, R., Ashton, C. and Goldson, A.L. Immediate breast reconstruction- impact on radiation management. *J. Natl. Med. Assoc.* 95: 286-295, 2003.

Oredipe, O.A., Furbert-Harris, P.M., Laniyan, I., Griffin, W.M. and Sridhar, R. Limits of stimulation of proliferation and differentiation of bone marrow cells of mice treated with swainsonine. *Int. J. Immunopharmacol.* 3: 1537-1547, 2003.

Oredipe, O.A., Furbert-Harris, P.M., Laniyan, I., Green, W.R., Griffin, W.M. and Sridhar, R. Coadministration of swainsonine and doxorubicin attenuates doxorubicin-induced lethality in

mice. Cell. Mol. Biol. 49: 1037-1048, 2003.

Oredipe, O.A., Furbert-Harris, P.M., Laniyan, I., Green, W.R., Griffin, W.M. and Sridhar, R. Mice primed with swainsonine are protected against doxorubicin-induced lethality. Cell. Mol. Biol. 49: 1089-1099, 2003.

Published Abstracts and Conference Presentations since 1998 (also includes articles unrelated to the grant)

Sridhar, R., Yamamoto, M., Patel, N.A. and Cooper, D.R. MCF-7 and MCF-7/ADR cells respond differently to changes in glucose concentrations. Presented at Experimental Biology 99" Washington, DC, April 17-21, 1999. FASEB J. Page A920, 1999 (Abstract # 682.4)

Kapadia, G.J., Hang, E., Sridhar, R., Mukainaka, T., Nishino, H. and Tokuda, H. Inhibition of phorbol ester-induced Epstein Barr early antigen activation by extracts of herbal remedies. Presented at the International meeting "2000 Years of Natural Product Research - Past, Present and Future", held in Amsterdam, Netherland, July 26-30, 1999. (Abstract # 512).

Cooper, D.R., Patel, N., Watson, J.E., Illingworth, P., Sridhar, R., Pillay, T.S., and Hanson-Painton, O. Insulin regulation of PKC pre-mRNA splicing and expression in 3T3-L1 adipocytes by PI3-kinase and cPKC signaling pathways. Endocrine Society Meeting, Toronto, Canada, June, 2000.

Wang, P.C., Liu, D., Agwu, E., and Sridhar, R. Application of P31 NMR spectroscopy to distinguish drug sensitive and drug resistant breast cancer. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume II, June 8-11, 2000, Atlanta, GA, pp684.

Zhou, Y., and Sridhar, R. Interaction of tamoxifen with doxorubicin. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume II, June 8-11, 2000, Atlanta, GA, pp 217.

Sridhar, R., Shankar, R.A., and Goldson, A.L. Novel approaches to radioprotection. Abstract of paper presented at 2000 Annual Convention and Scientific Assembly, National Medical Association, August 15, 2000.

Shankar, R.A., Zhou, Y., Goldson, A.L., and Sridhar, R. Hyperthermia induced cell death in human prostate cancer cells. Abstract of paper presented at the Residents Scientific Forum, 2000 Annual Convention and Scientific Assembly, National Medical Association, August 13, 2000.

Shankar, R.A., Zhou, Y., Goldson, A.L., and Sridhar, R. Hyperthermia induced cell death in human prostate cancer cells. Abstract of paper presented at the Fifteenth Annual Howard University Medical Center, Resident/Faculty Scientific Forum: May 10, 2000.

Shankar, R.A., Zhou, Y., Goldson, A.L., and Sridhar, R. Is Neurotoxicity of the radiosensitizer

Misonidazole related to Lipid Peroxidation? Abstract of paper presented at the Fall Resident/Faculty Scientific Forum and the fifth annual Charles S. Ireland Memorial lecture program: Dec 14, 2001.

Sridhar, R., and Desai, P.B. Similarities and differences in mechanisms of free radical formation from mitoxantrone and doxorubicin. Abstract presented at the Annual Meeting of American Association for Cancer Research, New Orleans, LA. 2001.

Sridhar, R., Balan, K.B., Shankar, R.A., Zhou, Y. and Goldson, A.L. Observations on the application of neutral red assay for cell viability. Abstract of presentation at EXPERIMENTAL BIOLOGY 2001, Orlando, FL, 2001.

Zhou, Y., Gu, X, Dhingra, S. and Sridhar, R. Nicotine inhibits doxorubicin –induced apoptosis of human breast cancer cells in culture. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, Abstract P10-25, September 26, 2002, Orlando, FL

Wang, P.C., Zhou, J., Agwu, C., Li, E. and Sridhar, R. An improved perfusion system for NMR study of breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume III, Abstract P40-30, September 28, 2002, Orlando, FL

Narayana, A., Apparaju, S., Gudelsky, G.A., Sridhar, R. and Desai, P.B. Investigation of the pharmacokinetics and pharmacodynamics of gemcitabine in glioma tumors: influence of ionizing radiation. Int. J. Radiat. Oncol. Biol. 54: Number 2, Supplement, 240, 2002. Abstract #2051.

Shankar, R.A., Kuppusamy, P., Zhou, Y., Goldson, A.L., Zweier, J. L. and Sridhar, R. In vivo measurements of tumor oxygenation and metabolism using electron paramagnetic resonance spectroscopy/imaging. Int. J. Radiat. Oncol. Biol. 54: Number 2, Supplement, 118, 2002. Abstract #198.

Shankar, RA., Zhou, Y., Goldson, AL and Sridhar, R. – Is Neurotoxicity of the Radiosensitizer Misonidazole Related to Lipid peroxidation? Oral presentation at the National Medical Association 2002 Scientific Assembly and Annual Meeting, Honolulu, Hawaii, Aug 04, 2002.

Apparaju, S., Gudelsky, G.A., Sridhar, R. and Desai, P.B. Evaluation of pharmacokinetics of gemcitabine in rat brain extracellular fluid employing *in vivo* microdialysis. Proc. Amer. Assoc. Cancer Res. 43: 210, March 2002 , Abstract # 1051.

Cooper, D. R., Patel, N. A., Chappel, D.S., Mebert, K., Mancu, D., Miller, L.A., Duong. T., Sridhar, R., Watson, J.E. and Eichler, D.C. Insulin-regulated inclusion of a protein kinase C beta II specific exon introduces an instability element responding to high glucose concentrations in vascular smooth muscle cells. Abstract of poster at the 41st Annual Meeting of the American Society of Cell Biology, December 8-12, 2001, Washington, DC.

Pang, X., Xie, T., Zhou, Y., Sridhar, R., Califano, J. and Gu, X. Apoptotic effect of salvionolic acid B in various cancer cells. Proc. Amer. Assoc. Cancer Res. 44: 2003, Abstract # 327.

Gu, X., Pang, X., Zhou, Y., Sridhar, R. and Califano, J. Nicotine inhibits vitamin E succinate induced apoptosis of human head and neck squamous cell carcinoma. Proc. Amer. Assoc. Cancer Res. 44: 2003, Abstract # 3894.

Zhou, Y., Sridhar, R., Gu, X., Pang, X., Balachandran, R., Magarian, R.A. and Day, B.W. Evaluation of a series of 1,1-dichloro-2,3-di- and tri-arylcyclopropanes as MDR reversing agents. Proc. Amer. Assoc. Cancer Res. 45: 2004, Abstract # 2139.

Gu, X., Song, X., Zhou, Y., Ji, H., Xie, T., Sridhar, R. and Pang, X. Comparison of nicotine effects in vitamin E succinate and 5-FU treated human head and neck squamous cell carcinoma. Proc. Amer. Assoc. Cancer Res. 45: 2003, Abstract # 3742.

Sadler, S., Zhou, Y., Zhang, R., Ashayeri, E. and Sridhar, R. Alkaline phosphatase activity of cancer cells: implications for the use of amifostine. Abstract of paper presented at the Fifteenth Annual Howard University Medical Center, Resident/Faculty Scientific Forum: May 5, 2004.

Ally, N., Zhou, Y., Zhang, R. and Sridhar, R. Chemomodulation of multidrug resistance of human breast cancer cells. Abstract of paper presented at the Fifteenth Annual Howard University Medical Center, Resident/Faculty Scientific Forum: May 5, 2004.

CONCLUSIONS

A robust analytical method has been established for carrying out pharmacokinetic studies on tumor bearing mice. The formation of free radicals during cellular metabolism of doxorubicin has been demonstrated. However, the conditions necessary for demonstrating free radical formation also caused extensive cell death. Tamoxifen is an efficient antioxidant which interacts synergistically with doxorubicin to kill multidrug resistant MCF-7/ADR cells. This has to be confirmed *in vivo* using solid tumor xenografts of MCF-7/ADR cells in nude mice. This will be accomplished in the next phase of the project. Raloxifene and toremephine will also be tested *in vivo* along with tamoxifen. Our experiments underscore the importance of glucose levels in modulating the proliferation rate and cytotoxic response of cells.

The MDR reversing agents, tamoxifen, dipyridamole and raloxifene partially inhibit doxorubicin mediated lipid peroxidation in tumor cells and in microsomal preparations. The results need to be confirmed using MCF-7, and MCF-7 MDR clone 10.3 cells developed by Dr. Michael Gottesman of the National Institutes for Health..

The MCF-7/ADR cells which was used in our studies has a mutated p53 and is not prone to undergo doxorubicin mediated apoptosis. Moreover this cell line may not even be a breast cancer. Therefore it is essential that we concentrate our efforts on MCF-7 and MCF-7 MDR clone 10.3. We also have MDA 435/LCC6 and its multidrug resistant derivative MDA/LCC6MR1 for comparison.

It is important to test the antiperoxidant and thiol sparing effects of tamoxifen, dipyridamole and

raloxifene using authentic breast cancer cells differing in drug sensitivities. These results should be compared with those obtained using cardiac muscle cells. Electron spin resonance studies should be carried out to evaluate the thiol tone of muscle cells and tumor cells treated with doxorubicin alone and in combination with tamoxifen, raloxifene and dipyridamole.

The MCF-7 and MCF-7 MDR clone 10.3 will be grown as solid tumor xenografts in Balb/c nude mice for completing the pharmacokinetic studies as proposed. The results from these studies will help identify any preferential effects of doxorubicin and multidrug reversing agents on the tumor in comparison to the heart.

REFERENCES

1. Myers, C.E., McGuire, W.P., Liss, R.H., Ifrim, I., Krotzinger, K. and Young, R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. *Science* 197: 165-167, 1977.
2. Olson, R.D. and Mushlin, P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *FASEB J.* 4: 3076-3086, 1990
3. Doroshow, J.H., Locker, J.Y., Ifrim, I. and Myers, C.E. Prevention of cardiac toxicity in the mouse by N-acetylcysteine. *J. Clin. Invest.* 68: 1053-1064, 1981
4. Pirnia, F., Breuleux, M., Schneider, E., Hochmeister, M., Bates, S.E., Marti, A., Hotz, M.A., Betticher, D.C. and Borner, M.M. Uncertain identity of doxorubicin-resistant MCF-7 cell line expressing mutated p53. *J. Natl. Cancer Inst.* 92: 1535-1536, 2000.
5. Mehta, K., Devarajan, E., Chen, J., Multani, A. and Pathak, S. Multidrug-resistant MCF-7 cells: an identity crisis? *J. Natl. Cancer Inst.* 94: 1652-1654, 2002
6. Scudiero, D.A., Monks, A. and Sausville, E.A. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. *J. Natl. Cancer Inst.* 90: 862, 1998.
7. Sridhar, R., Hanson-Painton, O. and Cooper, D.R. Protein kinases as therapeutic targets. *Pharmaceut. Res.* 17: 1345-1353, 2000.
8. O'Brian, C.A., Ward, N.E., Stewart, J.R. and Chu, F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer – an evolving story. *Cancer Metastasis Rev.* 20: 95-100, 2001.
9. Swannie, H.C. and Kaye, S.B. Protein kinase C inhibitors. *Curr. Oncol. Rep.* 4: 37-46, 2002.
10. Roepe, P.D. pH and multidrug resistance. *Novartis Found. Symp.* 240: 232-247, 2001.
11. Jones, K.H., Liu, J.J., Roehm, J.S., Eckel, J.J., Eckel, T.T., Stickrath, C.R., Triola, C.A., Jiang, Z., Bartoli, G.M., Cornwell, D.G. Gamma-tocopheryl quinone stimulates apoptosis in drug-sensitive and multidrug-resistant cancer cells. *Lipids*, 37: 173-184, 2002.
12. Shabbits, J.A., and Mayer, L.D. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. *Mol. Cancer Ther.* 1: 205-213, 2002.
13. Chen, J.S., Agarwal, N. and Mehta, K. Multidrug-resistant MCF-7 breast cancer cells contain deficient intercellular calcium pools. *Breast Cancer Res. Treat.* 71: 237-247, 2002.

14. Zhou, Y., Gu, X, Dhingra, S. and Sridhar, R. Nicotine inhibits doxorubicin –induced apoptosis of human breast cancer cells in culture. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, Abstract P10-25, September 25-28, 2002, Orlando, FL
15. Garrido, R., Mattson, M.P., Hennig, B. and Toborek, M. Nicotine oprotects against arachidionic acid induced caspase activation, cytochrome c release and apoptosis of cultured neurons. *J. Neurochem.* 76: 1395-1403, 2001.
16. Cormier, A., Morin, C., Zini, R., Tillement, J.P. and Lagrue, G. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. *Brain Res.* 900: 72-79, 2001.
17. Zidovetzki, R., Chen, P., Fisher, M., Hofman, F.M. and Faraci, F.M. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C – associated pathway. *Stroke* 30: 651-655, 1999.
18. Qiu, J., Lou, L.G., Huang, X.Y., Lou, S.J., Pei, G. and Chen, Y.Z. Nongenomic mechanisms of glucocorticoid inhibition of nicotine-induced calcium influx in PC12 cells: involvement of protein kinase C. *Endocrinology* 139: 5103-5108, 1998.
19. Heusch, W.L. and Maneckjee, R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. *Carcinogenesis* 19: 551-556, 1998.
20. Martin, D.S., Bertino, J.R., and Koutcher, J.R. ATP depletion plus pyrimidine depletion can markedly enhance cancer therapy: Fresh insight for a new approach. *Cancer Res.* 60: 6776-6783, 2000.
21. Wang, P.C., Zhou, J., Agwu, C.E., Li, E. and Sridhar, R. An improved perfusion system for NMR study of breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume III, Abstract P40-30, September 25-28, 2002, Orlando, FL
22. Sridhar, R., Yamamoto, M., Patel, N.A. and Cooper, D.R. MCF-7 and MCF-7/ADR cells respond differently to changes in glucose concentrations. *FASEB J.* 13: A920, 1999. Abstract # 682.14 presented at "EXPERIMENTAL BIOLOGY 99", Washington, DC, April 17-21, 1999.
23. Jeffrezou, J.P., Laurent, G. and Levade, T. Ceramide in regulation of apoptosis. Implication in multitoxicant resistance. *Subcell. Biochem.* 36: 269-284, 2002.
24. Lavie, Y., Cao, H., Volner, A., Lucci, A., Han, T., Geffen, V., Giuliano, A.E., and Cabot, M.C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. *J Biol. Chem.* 272: 1682-1687, 1997.

25. Ogretman, B. and Hannun, Y.A. Updates on functions of ceramide in chemotherapy-induced cell death in multidrug resistance. *Drug Resist. Updat.* 4: 368-377, 2001.
26. Liu, Y.Y., Han, T.Y., Giuliano, A.E. and Cabot, M.C. Ceramide glycosylation potentiates multidrug resistance. *FASEB J.* 15: 719-730, 2001.
27. Olshefski, R.S. and Ladisch, S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. *Int. J. Cancer* 93: 131-138, 2001.
28. Sietsma, H., Veldman, R.J. and Kok, J.W. The involvement of sphingolipids in multidrug resistance. *J. Membr. Biol.* 181: 153-162, 2001.
29. Morjani, H., Aouali, N., Belhoussaine, R., Veldman, R.J., Levade, T. and Manfait, M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation
30. Sridhar, R., and Desai, P.B. Similarities and differences in mechanisms of free radical formation from mitoxantrone and doxorubicin. Abstract presented at the Annual Meeting of American Association for Cancer Research, New Orleans, LA. 2001. *Proc. Amer. Assoc. Cancer Res.* 42: 935, 2001 (Abstract # 5017).
31. Sridhar, R., Balan, K.B., Shankar, R.A., Zhou, Y. and Goldson, A.L. Observations on the application of neutral red assay for cell viability. Abstract of presentation at EXPERIMENTAL BIOLOGY 2001, Orlando, FL, 2001. *FASEB J.* 15(4): pp A238, 2001.

APPENDICES LIST

- #1. Figure 1 : Calibration curve for HPLC analysis of doxorubicin
- #2. Table 1: Intra-day and inter-day reproducibility of HPLC analysis of doxorubicin
Table 2: Efficiency of acid extraction method for recovery of doxorubicin from Mouse plasma
- #3. Figure 2: The influence of glucose on proliferation of MCF-7 and MCF-7/ADR cells in culture
- #4. Figure 3: Survival curves for MCF-7 cells treated with graded concentrations of doxorubicin with or without tamoxifen
- #5. Figure 4: Survival curves for MCF-7/ADR cells treated with graded concentrations doxorubicin with or without tamoxifen
- #6. Table 3: Enhancement of doxorubicin cytotoxicity by tamoxifen
- #7. Figure 5: Isobologram analysis of cell survival data on MCF-7 cells
- #8. Figure 6: Isobologram analysis of cell survival data on MCF-7/ADR cells
- #9. Figure 7: Comparison of doxorubicin semiquinone free radical production during anaerobic metabolism of MCF-7 and MCF-7/ADR cells
- #10. Figure 8: Comparison of hydroxyl free radical production in aerobic incubations of MCF-7 and MCF-7/ADR cells containing the spin trap (DMPO) and doxorubicin with or without tamoxifen
- #11. Figure 9: Inhibition of cardiac microsomal lipid peroxidation by tamoxifen
- #12. Figure10: Influence of tamoxifen on doxorubicin induced lipid peroxidation in rat liver microsomes
- #13. Figure 11: Effect of doxorubicin concentration on microsomal lipid peroxidation
- #14. Effect of nicotine on doxorubicin toxicity towards MCF-7 and KB3.1 cells
- #15. Schematic outline of sequential biochemical pathways to apoptosis induced by doxorubicin.
- #16. Sphingomyelin-ceramide pathway for apoptosis.
- #17. Abstract: Sridhar, R., and Desai, P.B. Similarities and differences in mechanisms of free

- radical formation from mitoxantrone and doxorubicin. Abstract presented at the Annual Meeting of American Association for Cancer Research, New Orleans, LA. 2001. Proc. Amer. Assoc. Cancer Res. 42: 935,2001. (abstract #5017).
- #18. Neutral red assay for cell viability is not reliable
 - #19. Abstract: Wang, P.C., Liu, D., Agwu, E. and Sridhar, R. Application of P31 NMR spectroscopy to distinguish drug sensitive and drug resistant breast cancer. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, June 8-11, 2000, Atlanta, GA, pp 217.
 - #20. Abstract: Wang, P.C., Zhou, J., Agwu, C.E., Li, E. and Sridhar, R. An improved perfusion system for NMR study of breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume III, Abstract P40-30, September 25-28, 2002.
 - #21. Abstract: Zhou, Y. and Sridhar, R. Interaction of tamoxifen with doxorubicin. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume II, June 8-11, 2000, Atlanta, GA. pp 684.
 - #22. Abstract: Zhou, Y., Gu, X., Dhingra, S. and Sridhar, R. Nicotine inhibits doxorubicin-induced apoptosis of human breast cancer cells in culture. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, Abstract P10-25, September 25-28, 2002, Orlando, FL
 - #23. Abstract: Sridhar, R., Balan, K.B., Shankar, R.A., Zhou, Y. and Goldson, A.L. Observations on the application of neutral red assay for cell viability. Abstract of presentation at EXPERIMENTAL BIOLOGY 2001, Orlando, FL, 2001. FASEB J. 15 (4): pp a238, 2001.
 - #24. Publication: Sridhar, R., Hanson-Painton, O. and Cooper, D.R. Protein kinases as therapeutic targets. Pharmaceut. Res. 17: 1345-1353, 2000.
 - #25. Sensitization of multidrug resistance of MCF-7 clone 10.3 cells to doxorubicin by loperamide.
 - #26. Abstract: Zhou, Y., Sridhar, R., Gu, X., Pang, X., Balachandran, R., Magarian, R.A. and Day, B.W. Evaluation of a series of 1,1-dichloro-2,3-di- and tri-arylcyclopropanes as MDR reversing agents. Proc. Amer. Assoc. Cancer Res. 45: 2004, Abstract # 2139.
 - #27. Manuscript: Ally, N., Zhou, Y., Zhang, R. and Sridhar, R. Chemomodulation of multidrug resistance of human breast cancer cells *in vitro*. (In preparation).
 - #28. Sridhar, R., Yamamoto, M., Patel, N.A. and Cooper, D.R. MCF-7 and MCF-7/ADR cells respond differently to changes in glucose concentrations. Presented at Experimental Biology 99" Washington, DC, April 17-21, 1999. FASEB J. Page A920, 1999 (Abstract # 682.4)




Figure 1: Calibration Curve for HPLC Analysis of Doxorubicin

HPLC analysis was carried out on samples containing known amounts of doxorubicin (DOX) and daunomycin (DAUN) as the internal standard. Spherisorb ODS-2 column (5 μ 4.6 mm x 25 cm column) was used in a Shimadzu HPLC system equipped with a fluorescence detector. A 70:30 mixture of phosphate buffer (pH 0.06 M; pH 4.0) and acetonitrile was used for isocratic elution at a flow rate of 1 ml per minute, at room temperature. Fluorescence detector was at excitation and emission wave lengths of 480 nm and 560 nm respectively. Doxorubicin and daunomycin eluted after retention times of 7.5 and 17.5 minutes respectively.

APPENDIX 1

| Concentration of | Percent Variation | Coefficient of |
|---------------------|-------------------|----------------|
| Doxorubicin (ng/ml) | Intra-day | Inter-day |
| 25 | 4.2 | 6.9 |
| 125 | 5.8 | 6.0 |

Table 1: Intra-day and inter-day reproducibility of HPLC analysis of doxorubicin


Plasma samples containing known amounts of doxorubicin were subjected to the acid extraction procedure and analyzed using HPLC and the inter-day and intra-day variation was checked.

| Concentration of Doxorubicin added (ng/ml) | Concentration of Doxorubicin recovered | Percent recovery (mean \pm standard deviation) |
|--|--|--|
| 25 | 23.3, 26.4, 23.9 | 98.1 \pm 5.36 |
| 50 | 45.9, 48.1, 53.7 | 98.4 \pm 6.56 |
| 100 | 94.5, 93.8, 96.7 | 95.0 \pm 1.23 |


Table 2: Efficiency of acid extraction method for recovery of doxorubicin from mouse plasma.

Plasma samples were thawed and mixed using a vortex generator. one hundred microliters of plasma were spiked with an equal volume of daunomycin (5 μ M) as an internal standard and then mixed with 300 μ l of 0.6 N HCl in 90% ethanol and stored at 4°C for one hour to form a gel. The sample was then centrifuged at 20,000 g for 25 minutes and the clear supernatant was analyzed for doxorubicin. Since doxorubicin and daunomycin are photosensitive, all manipulations were performed under subdued light.

APPENDIX 2



MCF 7



MCF 7/ADR

Figure 2: The influence of glucose on proliferation of MCF-7 and MCF-7/ADR cells in culture

The effects of glucose concentration on cell proliferation were investigated in MCF-7 (left panel) and MCF-7/ADR (right panel) cells. Single cell suspensions were prepared from exponentially growing monolayer cultures. Cells were seeded in several 6 well plates at approximately 1×10^4 cells/well in 3 ml of RPMI 1640 medium containing 5% fetal bovine serum and normal (5 mM) (open circle) or high (25 mM) (open square) glucose. Total viable cell counts were determined daily using 0.4% trypan blue dye exclusion and the number of cells per dish calculated. the proliferation rate of MCF-7/ADR cells was higher than that of MCF-7 cells at normal glucose concentration. The proliferation of MCF-7 cells was stimulated by high glucose (top panel) but there was no difference in the proliferation rates of MCF-7/ADR cells exposed to normal and high glucose (lower panel). Data are mean \pm SD for triplicate determinations which were repeated in three separate experiments.

APPENDIX 3




Figure 3: Cell survival curves for MCF-7 cells treated with graded concentrations of doxorubicin with or without tamoxifen

Cell viability was assessed using clonogenicity measurements. Appropriate numbers of exponentially growing MCF-7 cells were plated in triplicate onto 60 x 15 mm tissue culture dishes containing 5 ml complete medium. Cultures were treated the next day with doxorubicin (0 to 20 μ M) alone (closed circle) or with tamoxifen (10 μ M) (open circle) for 6 hours. At the end of the 6 hour drug treatment, the medium containing the drug was removed, and the cultures were washed with phosphate buffered saline and replenished with fresh medium. The cultures were incubated for 10 to 12 days and then stained with 1% methylene blue in 50% ethanol. Colonies containing 50 or more cells were considered to be reproductively viable. Survival of cells with respect to untreated controls was plotted against doxorubicin concentration.

APPENDIX 4




Figure 4: Cell survival curves for MCF-7/ADR cells treated with graded concentrations of doxorubicin with and without tamoxifen.

Cell viability was assessed using clonogenicity measurements. Appropriate numbers of exponentially growing MCF-7/ADR cells were plated in triplicate onto 60 x 15 mm tissue culture dishes containing 5 ml complete medium. Cultures were treated the next day with doxorubicin (0 to 75 μM) alone (closed circle) or with tamoxifen (10 μM) (open circle) for 6 hours. At the end of the 6 hour drug treatment, the medium containing the drug was removed, and the cultures were washed with phosphate buffered saline and replenished with fresh medium. The cultures were incubated for 10 to 12 days and then stained with 1% methylene blue in 50% ethanol. Colonies containing 50 or more cells were considered to be reproductively viable. Survival of cells with respect to untreated controls was plotted against doxorubicin concentration.

APPENDIX 5

| Tamoxifen (μ M) | MCF-7 CELLS | | MCF-7/ ADR CELLS | |
|----------------------|-------------------------------------|---------------------------|-------------------------------------|---------------------------|
| | Dox (μ M) IC ₅₀ | Enhancement Index (EI) | Dox (μ M) IC ₅₀ | Enhancement Index (EI) |
| 0.0 | 0.96 | - | 25.0 | - |
| 1.0 | 0.91 | 1.1 | 20.5 | 1.2 |
| 2.0 | 0.76 | 1.3 | 15.9 | 1.6 |
| 5.0 | 0.47 | 2.0 | 5.1 | 4.9 |
| 10.0 | 0.06 | 16.0 | 0.7 | 35.7 |

Table 3: Enhancement of doxorubicin cytotoxicity by tamoxifen

Appropriate numbers of exponentially growing MCF-7 and MCF-7/ADR cells were plated in triplicate onto 60 x 15 mm tissue culture dishes containing 5 ml of complete RPMI 1640 medium. Doxorubicin (0 to 20 μ M in case of MCF-7 cells; 0 to 75 μ M in the case of MCF-7/ADR cells) and / or tamoxifen (0 to 10 μ M) were added the next day. After 6 hours of drug treatment, the medium was removed from the cultures which were subsequently washed with phosphate buffered saline, and then refed with complete medium. The cultures were incubated for another 10 to 12 days and then stained with methylene blue (1% solution in 50 % ethanol). Colonies containing 50 or more cells were considered to represent a viable cell. The number of colonies arising from viable cells was determined and the survival was calculated relative to untreated control cultures. and the dose response curves were plotted and analyzed by the method of Chou and Talalay (4) to determine IC₅₀ values. The enhancement index (EI) was calculated as the ratio

$$\frac{(\text{IC}_{50} \text{ of Doxorubicin in the absence of Tamoxifen})}{(\text{IC}_{50} \text{ of Doxorubicin in the presence of Tamoxifen})}$$

APPENDIX 6




Figure 5: Isobologram analysis of cell survival data on MCF-7 cells

The nature of the interaction of doxorubicin and tamoxifen was evaluated according to the method of Berenbaum (5). Since each drug was cytotoxic when used alone, the combination of doxorubicin and tamoxifen was considered homoergic. Cells were treated with tamoxifen alone or doxorubicin alone or combinations of the two drugs over a range of concentrations and IC_{50} values were determined as indicated in table 3. The IC_{50} isobole was constructed and the combination of tamoxifen and doxorubicin was found to act additively.




Figure 6: Isobologram analysis of cell survival data on MCF-7/ADR cells

The nature of the interaction of doxorubicin and tamoxifen was evaluated according to the method of Berenbaum (5). Since each drug was cytotoxic when used alone, the combination of doxorubicin and tamoxifen was considered homoergic. Cells were treated with tamoxifen alone or doxorubicin alone or combinations of the two drugs over a range of concentrations and IC_{50} values were determined as indicated in table 3. The IC_{50} isobole was constructed and the combination of tamoxifen and doxorubicin was found to act synergistically.




Figure 7: Comparison of doxorubicin semiquinone free radical production during anaerobic metabolism of doxorubicin by MCF-7 and MCF-7/ADR cells

Single cell suspensions were prepared from exponentially growing monolayer cultures. Anaerobic incubations were carried out in closed sample vials (2 ml capacity) containing (10^7 cells/ml) in phosphate buffered saline (pH 7.4), glucose (0.2 mM) and doxorubicin (0.1 mM). The samples were transferred anaerobically into an ESR sample cell after incubation at 37°C and the spectra recorded over a 60 minute period in order to assess the kinetics of semiquinone formation. The relative intensity of the adriamycin semiquinone signal was plotted against the duration of incubation. Inclusion of tamoxifen (10 μ M) did not affect the formation of semiquinone free radical. The signal due to doxorubicin semiquinone was higher in the case of MCF-7 cells compared to MCF-7/ADR cells. It is important to mention that the concentration of doxorubicin used in these experiments cause reproductive death of almost all the cells. The two cell lines differ in their tolerance or sensitivity to doxorubicin.

APPENDIX 9




Figure 8: Comparison of hydroxyl free radical production in aerobic incubations of MCF-7 and MCF-7/ADR cells containing the spin trap (DMPO) and doxorubicin with or without tamoxifen

For these experiments, aerobic incubation mixtures contained 10^7 cell per ml in phosphate buffer (pH 7.4), glucose (2 mM), doxorubicin (100 μ M) and DMPO (100 μ M) with or without tamoxifen (10 μ M). Aeration was ensured by bubbling air through the incubation mixture maintained at 37°C. Electron spin resonance spectra were acquired at different times over a period of 1 hour. The intensity of the second peak of the 1:2:2:1 quartet of the DMPO-OH signal was plotted against duration of incubation.




Figure 9: Inhibition of cardiac microsomal lipid peroxidation by tamoxifen.

Incubation mixtures contained 3 mg microsomal protein per ml, 2.5 mM NADPH with or without doxorubicin (25 μ M) and tamoxifen (0 to 25 μ M). Malonaldehyde was determined by measuring the absorbance at 532 nm of the 2-thiobarbituric acid conjugation product after processing with thiobarbituric acid reagent under acidic conditions (6). Lipid peroxidation was allowed to proceed for 60 minutes. No effort was made to exclude adventitious iron in the buffers or reagents used.




Figure 10: Influence of tamoxifen on doxorubicin induced lipid peroxidation in liver microsomes

Incubation mixtures contained 1 mg of microsomal protein per ml and an NADPH generating system composed of glucose -6-phosphate (5 mM), NADP (0.3 mM) and 0.5 units of D-glucose-6-phosphate dehydrogenase. Lipid peroxidation was determined on the basis of 2-thiobarbituric acid reactive substances which have a strong absorbance at 532 nm (6). Lipid peroxidation was allowed to proceed at 37°C for 60 minutes in the presence or absence of doxorubicin (25 μ M) with or without tamoxifen (10 μ M)




Figure 11: Effect of doxorubicin concentration on microsomal lipid peroxidation.

Incubation mixtures contained 1 mg of microsomal protein per ml and an NADPH generating system and graded concentrations of doxorubicin (0 to 150 μM) with or without tamoxifen (10 μM). Lipid peroxidation was allowed proceed for 60 minutes at 37°C and the extent of peroxidation was assayed by measuring 2-thiobarbituric acid reactive substances (6).

APPENDIX 14

Effect of nicotine on doxorubicin toxicity towards MCF-7 and KB3.1 cells

Introduction

In the United States approximately 7.5 % of cancer related deaths can be attributed to smoking. Tobacco use has been associated with carcinogenesis. Tobacco use is strongly discouraged in patients undergoing cancer therapy. Nicotine (nic) may decrease the effectiveness of cancer therapy and increase the risk of tumor recurrence.

The aim of cancer therapy is to eliminate clonogenic cells in tumor. Clonogenicity assays are useful for determining reproductive cell death, whereas assays for apoptosis are not always a measure of reproductive death in cells. Tumor recurrence depends on the presence of viable clonogenic cells that survive even after therapy. We tested the effect of nicotine on cytotoxicity of doxorubicin(dox) towards cancer cells in culture, using assays for apoptosis, necrosis and clonogenicity.

Methods and Materials

Cells: MCF-7 human breast cancer cells and KB-3.1 human nasopharyngeal carcinoma cells were cultured and maintained as exponential monolayers in a humidified 5% carbon dioxide air atmosphere in a 37°C incubator. RPMI 1640 medium fortified with 10% fetal bovine serum, glutamine (2mM), sodium pyruvate (1mM) and 100 units/ml each of penicillin and streptomycin was used for culturing MCF-7 cells. KB-3.1 cells were grown in Dulbecco's minimum essential medium that was fortified with fetal bovine serum, glutamine, pyruvate and antibiotics as indicated for RPMI 1640.

Apoptosis assays: Annexin V-EGFP apoptosis detection kit (MBL, Nagoya, Japan) was used for apoptosis assays using a flow cytometer. Apoptosis was estimated by measuring caspase 3 and caspase 8 activities using a caspase-3/CPP32 fluorometric protease assay kit and a caspase-8/Flice fluorometric protease assay kit (MBL, Nagoya, Japan). Apoptosis was also detected on the basis of DNA Fragmentation analysis using 1.5% agarose gels, using ethidium bromide for staining.

Clonogenicity assay: Cells were seeded at a density of 300 and 1500 cells per 60mm diameter tissue culture dishes and the cells were allowed to attach overnight. The cultures were treated with nicotine (10 or 20 μ M) for two hours. Control cultures were treated with same volume of medium without nicotine. After the two hour exposure to nicotine, the cultures were treated with different concentrations of doxorubicin (0.25 to 10 μ M range) for 90 or 120 minutes. Appropriate controls without doxorubicin were also included. The medium was removed from each dish and the cells were washed with Dulbecco's phosphate buffered saline, and fresh drug free culture medium (5 ml) was added and the cultures returned to the incubator for colony formation to progress for ten days. Any colony containing more than 50 cells was considered to represent a viable clonogenic cell. The number of colonies in the different dishes were counted after staining with methylene blue. Survival was calculated relative to a 100% value for untreated controls. The experiment was performed at least four times for each cell line.

APPENDIX 14

Effect of nicotine on doxorubicin toxicity towards MCF-7 and KB3.1 cells

Introduction

In the United States approximately 7.5 % of cancer related deaths can be attributed to smoking. Tobacco use has been associated with carcinogenesis. Tobacco use is strongly discouraged in patients undergoing cancer therapy. Nicotine (nic) may decrease the effectiveness of cancer therapy and increase the risk of tumor recurrence.

The aim of cancer therapy is to eliminate clonogenic cells in tumor. Clonogenicity assays are useful for determining reproductive cell death, whereas assays for apoptosis are not always a measure of reproductive death in cells. Tumor recurrence depends on the presence of viable clonogenic cells that survive even after therapy. We tested the effect of nicotine on cytotoxicity of doxorubicin(dox) towards cancer cells in culture, using assays for apoptosis, necrosis and clonogenicity.

Methods and Materials

Cells: MCF-7 human breast cancer cells and KB-3.1 human nasopharyngeal carcinoma cells were cultured and maintained as exponential monolayers in a humidified 5% carbon dioxide air atmosphere in a 37°C incubator. RPMI 1640 medium fortified with 10% fetal bovine serum, glutamine (2mM), sodium pyruvate (1mM) and 100 units/ml each of penicillin and streptomycin was used for culturing MCF-7 cells. KB-3.1 cells were grown in Dulbecco's minimum essential medium that was fortified with fetal bovine serum, glutamine, pyruvate and antibiotics as indicated for RPMI 1640.

Apoptosis assays: Annexin V-EGFP apoptosis detection kit (MBL, Nagoya, Japan) was used for apoptosis assays using a flow cytometer. Apoptosis was estimated by measuring caspase 3 and caspase 8 activities using a caspase-3/CPP32 fluorometric protease assay kit and a caspase-8/Flice fluorometric protease assay kit (MBL, Nagoya, Japan). Apoptosis was also detected on the basis of DNA Fragmentation analysis using 1.5% agarose gels, using ethidium bromide for staining.

Clonogenicity assay: Cells were seeded at a density of 300 and 1500 cells per 60mm diameter tissue culture dishes and the cells were allowed to attach overnight. The cultures were treated with nicotine (10 or 20 μ M) for two hours. Control cultures were treated with same volume of medium without nicotine. After the two hour exposure to nicotine, the cultures were treated with different concentrations of doxorubicin (0.25 to 10 μ M range) for 90 or 120 minutes. Appropriate controls without doxorubicin were also included. The medium was removed from each dish and the cells were washed with Dulbecco's phosphate buffered saline, and fresh drug free culture medium (5 ml) was added and the cultures returned to the incubator for colony formation to progress for ten days. Any colony containing more than 50 cells was considered to represent a viable clonogenic cell. The number of colonies in the different dishes were counted after staining with methylene blue. Survival was calculated relative to a 100% value for untreated controls. The experiment was performed at least four times for each cell line.

Results

Colony formation Assays: A 90 minute exposure of MCF-7 cells to doxorubicin (10 μ M) in the absence of nicotine killed all cells. However, pretreatment with 10 and 20 μ M nicotine afforded partial protection to MCF-7 cells treated with doxorubicin (10 μ M) (Fig. 1).

In KB-3.1 cells the survival was 14.2% after a 90 minute treatment with 0.5 μ M doxorubicin alone, but the survival increased to 27.2% when a two hour treatment with 10 μ M nicotine preceded doxorubicin (0.5 μ M) treatment (Fig. 2). Even this slight inhibition of doxorubicin cytotoxicity by nicotine will have a profound effect on tumor control. This is illustrated by simulating the effect of multiple treatments with doxorubicin alone and in the presence of nicotine. The graph (Fig. 3) depicts the number of clonogens remaining after multiple course of treatment of a hypothetical one gram tumor containing 10^9 clonogenic cells at the start of therapy. In this depiction, it is assumed that the tumor is homogeneous and that the effectiveness is the same for each cycle of therapy. Effects of tumor cell proliferation have also been ignored in this case.

Annexin V assay: Two color flow cytometry results indicated that a large proportion of cells exposed to doxorubicin were necrotic (as judged by propidium iodide staining) and the population of apoptotic cells was small. Pretreatment with nicotine (10 μ M) decreased necrosis due to doxorubicin (10 μ M) treatment of MCF-7 cells (Fig. 4 and 5). Nicotine treatment also protected KB 3.1 cells from necrosis induced by doxorubicin (1 μ M) treatment for 90 and 120 minutes (Fig. 6).

Caspase 3 and caspase 8 activities and DNA fragmentation: Treatment with 10 μ M doxorubicin alone for 90 minutes increased caspase-3 activity to 142% and caspase-8 activity to 126% relative to 100% activity for each enzyme in untreated control cultures. However, a 2 hour pre-treatment with 20 μ M nicotine reduced the caspase-3 and caspase-8 activities respectively, in cultures treated with doxorubicin to 114% and 101% of control (Fig. 7). This corresponds to a 20% inhibition of doxorubicin-induced apoptosis by 20 μ M nicotine in these cells. In a parallel set of experiments, the drug containing medium was replaced with drug free medium after the 90 minute exposure to doxorubicin and then incubated at 37°C for 24 hours. When these cells were examined, inhibition of doxorubicin-induced apoptosis by nicotine could be demonstrated on the basis of DNA fragmentation analysis (Fig. 8).

Our original intention was to compare MCF-7 and multidrug resistant MCF-7/ADR cells. Based on karyotype analysis, these cell lines were determined to be unrelated. However, we were able to obtain drug sensitive (KB-3.1) and related multidrug resistant (KB-V.1) nasopharyngeal carcinoma cells. We initiated experiments on these cells and used the results for comparison with the data for MCF-7 cells.

Conclusion

Nicotine decreases the cytotoxicity of doxorubicin as judged by assays for apoptosis, necrosis and clonogenicity. Necrosis and not apoptosis is the major cause of cell death in MCF-7 and KB-3.1 cells treated with doxorubicin under the conditions of our experiments. MCF-7 and KB-3.1 cells showed only a weak apoptotic response to doxorubicin treatment.

Inhibition of apoptosis and reproductive cell death can affect tumor control. This statement must further be tempered by the fact that tumor response to therapy depends on tumor cell killing, cell proliferation, and cell loss factor. Chemotherapy is usually given in multiple doses or cycles of treatment. The slight inhibition of doxorubicin cytotoxicity by nicotine can be detrimental to the efficacy of multiple courses of doxorubicin treatment.

The U.S. Army Medical Research Materiel Command under DAMD 17-98-1-8109 supported this work.

Fig 1. Partial inhibition of doxorubicin cytotoxicity by nicotine as demonstrated by clonogenicity assays in MCF-7 cells




Fig 2. Partial inhibition of doxorubicin cytotoxicity by nicotine as demonstrated by clonogenicity assays in KB-3.1 cells




Fig 3. Theoretical curves for treatment efficacy




Fig 4. Flow cytometry assays for apoptosis and necrosis in MCF-7 cells




Fig 5. Partial inhibition of doxorubicin induced necrosis in MCF-7 cells by nicotine (Flow cytometry analysis)




Fig 6. Flow cytometry assays for apoptosis and necrosis in KB-3.1 cells




Fig 7. Caspase assays for apoptosis in MCF-7 cells




Fig 8. DNA fragmentation assays in MCF-7 Cells

A: Nicotine 10 μ M,

B: Nicotine 20 μ M,


C: Nicotine 10 μ M+Doxorubicin 10 μ M,

D: Nicotine 20 μ M+Doxorubicin 10 μ M,


E: Control,

F: Doxorubicin 10 μ M.

The results from DNA fragmentation assay indicated that doxorubicin induced most DNA fragments (Lane F) compared to other treatment groups. However, 20 μ M nicotine inhibited this effect of doxorubicin (Lane D)




APPENDIX 15



Schematic outline of sequential biochemical pathways to apoptosis induced by doxorubicin
Based on Martin D.S. *et al.*, Reference 28

APPENDIX 16



APPENDIX 17

Abstract: Sridhar, R., and Desai, P.B. Similarities and differences in mechanisms of free radical formation from mitoxantrone and doxorubicin. Abstract presented at the Annual Meeting of American Association for Cancer Research, New Orleans, LA. 2001. Proc. Amer. Assoc. Cancer Res. 42: 935, 2001. (abstract #5017).

#5017 Similarities and Differences in Mechanisms of Free Radical Formation from Mitoxantrone and Doxorubicin. Rajagopalan Sridhar and Pankaj B. Desai. College of Pharmacy, University of Cincinnati, Cincinnati, OH, and Howard University Hospital and Cancer Center, Washington, DC.

Mitoxantrone is used for treating doxorubicin resistant breast cancer. Mitoxantrone is less cardiotoxic than doxorubicin. Since cardiotoxicity may involve free radical intermediates of drug metabolism, doxorubicin and mitoxantrone were evaluated for their tendencies to yield free radical species upon enzymatic reduction and oxidation. Doxorubicin, mitoxantrone and p-benzoquinone were each metabolized by rat liver microsomes and NADPH under anaerobic conditions to their corresponding semiquinone radicals as confirmed by their electron spin resonance (ESR) spectra. Interestingly, mitoxantrone (40 μ M) inhibited NADPH driven microsomal lipid peroxidation by 80%, whereas doxorubicin at the same concentration stimulated peroxidation nearly two fold. NADPH driven lipid peroxidation of rat liver microsomes, was estimated by the 2-thiobarbituric acid assay. Treatment of mitoxantrone (100 μ M) with horseradish peroxidase (HRP) and hydrogen peroxide (0.2 M potassium phosphate buffer, pH 7) yielded free radicals whose ESR spectrum was recorded. This matched the spectrum obtained for the product of HRP catalyzed attack of hydrogen peroxide on p-phenylenediamine. Spectrophotometric studies with this system showed the decay of characteristic peaks of mitoxantrone at 808 and 862 nm with concomitant build up of a peak at 586 nm. Treatment of doxorubicin with horseradish peroxidase and hydrogen peroxide caused rapid fading of the red color of the drug, but no free radical species could be detected by ESR spectroscopy. When tested at 10 μ M against MCF-7 cells in tissue culture, mitoxantrone was more toxic than doxorubicin. Mitoxantrone, in sharp contrast to doxorubicin, yielded a relatively stable free radical upon enzymatic oxidation. This could explain some of the differences in the pharmacodynamics of the two drugs. (Supported in part by the U.S. Army Medical Research and Materiel Command under DAMD17-98-1-8108)

APPENDIX 18




Fig 1. Comparison of Neutral Red and Clonogenicity Assays




Fig 2. Comparison of Neutral Red Uptake By Drug Sensitive and Multidrug Resistant Cells

APPENDIX 19

Abstract: Wang, P.C., Liu, D., Agwu, E. and Sridhar, R. Application of P31 NMR spectroscopy to distinguish drug sensitive and drug resistant breast cancer. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, June 8-11, 2000, Atlanta, GA, pp 217.

APPLICATION OF P31 NMR SPECTROSCOPY TO DISTINGUISH DRUG SENSITIVE AND DRUG RESISTANT BREAST CANCER

Dr. Paul C. Wang, Dr. Dongsheng Liu, Mr. Emmanuel Agwu, and Dr. Rajagopalan Sridhar

Department of Radiology, Howard University
Washington, DC 20060

E-mail: pwang@howard.edu

Nuclear magnetic resonance (NMR) spectroscopy has emerged as one of the most promising techniques to improve specificity in the diagnosis and staging of breast cancer. It has been widely used in the study of tumor energy metabolism, vasculature and oxygenation, and response to drug treatment. The NMR technique has intrinsically weak signals, which limit the ultimate resolution and sensitivity. A new NMR probe was constructed using a high temperature superconductor, YBCO, to reduce electronic noise and improve detection sensitivity. To test the improvement of sensitivity, two experiments are conducted: an *in vitro* cell metabolism study on 9.4 T spectrometer and an *in vivo* tumor-bearing animal study on a 4.7 T scanner.

In the cell metabolism study, MCF7 human breast cancer cells and their variants are used to characterize the differences in levels of phosphate metabolites during growth phase as well as under Tamoxifen and Doxorubicin treatment. During the NMR study, the breast cancer cells ($\sim 10^7$ cells) are restrained in agarose gel-thread matrices and continuously perfused with nutrients. Phosphorus metabolites identified include phosphocholine, inorganic phosphate, adenosine triphosphate, diphosphodiester, glycerophosphoethanolamine and glycerophosphocholine. The study of drug effect takes 10 to 12 hours, in which a series of NMR spectra are obtained at one hour intervals (4000 transients, 1.1 sec repetition time). The drug sensitive cells were dramatically affected by 2 μ M Doxorubicin within two hours of perfusion but not responsive to Tamoxifen within 12 hours. In contrast, MCF7/ADR multidrug resistant cells showed no effect by perfusion of 2 μ M Doxorubicin.

In the animal study, healthy female athymic nude mice (20-25 g) are used. MCF7 wild type and drug resistant cells are grown as solid tumor xenografts in one hind leg. The other non-involved leg served as a control. The NMR spectroscopy study of tumor progression is done every two or three days during the tumor growth phase. There is a significant drop in high energy phosphate signals in the tumor sites compared with the control sites. In the course of tumor progression, the level of high-energy phosphates continuously dropped while that of inorganic phosphate increased. This study has demonstrated the importance of high quality NMR spectra in differentiating drug sensitive and drug resistant cells.

The U.S. Army Medical and Material Command under DAMD17-96-1-6289 supported this work.

APPENDIX 20

Abstract: Wang, P.C., Zhou, J., Agwu, C.E., Li, E. and Sridhar, R. An improved perfusion system for NMR study of breast cancer cells. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume III, Abstract P40-30, September 25-28, 2002.

AN IMPROVED PERFUSION SYSTEM FOR NMR STUDY OF BREAST CANCER CELLS

Paul C. Wang, Jianwei Zhou, Chikizirim E. Agwu,
Ercheng Li, and Rajagopalan Sridhar

Department of Radiology, Howard University
Washington, DC 20060

pwang@howard.edu

Ex vivo nuclear magnetic resonance is useful for studying the metabolic activity and the response of cells to chemotherapy agents. Such studies involve data acquisition over extended periods up to several days. It is important to preserve the integrity of cells during such prolonged studies by providing adequate nutrients and oxygen to the cells by perfusing aerated culture medium maintained at the normal physiological temperature of 37°C. The presence of serum in the culture medium and temperature fluctuations can produce gas bubbles in the perfusion system. Air bubbles perturb magnetic field homogeneity in the NMR sample and causes line width broadening and loss of spectral resolution. We have utilized an improved perfusion system, which includes positive and negative pressure traps to prevent air bubble generation inside the NMR sample tube. This system has been used to prolong a typical 12 hour ex vivo study to longer than 10 days.

Wild type MCF-7 human breast cancer cells were grown to about 85% confluence in IMEM with 10% FBS. Approximately $1-2 \times 10^6$ cells were harvested and mixed with low temperature gelling agarose. The agarose-cell mixture was extruded into a NMR tube through a 0.5 mm i.d. Teflon tubing. This resulted in thin strands of spaghetti like threads containing cells embedded in agarose. These threads in the NMR tube were perfused with IMEM (0.9 ml/min) using a peristaltic pump, with strategically located air bubble traps before and after the pump and a reservoir for waste collection was located to collect the effluent from the NMR tube. A 400 MHz instrument was used with a repetition time 2 sec, flip angle 45°, spectral width of 5000 Hz and 1800 transients were acquired over an hour. The ex vivo studies were performed at 37° C and deuterium locked. Many phosphorus metabolites were identified on the basis of their chemical shifts and by spiking with the appropriate authentic compound, in particular phosphoethanolamine (PE), phosphocholine (PC), inorganic phosphate (Pi), glycerophospho-ethanolamine (GPE), glycerophosphocholine (GPC), phosphocreatine (PCr), γ -adenosine triphosphate (γ -ATP), α -adenosine triphosphate (α -ATP), diphosphodiester (DPDE), and β -adenosine triphosphate (β -ATP). The stability of the perfusion system was demonstrated over ten days by comparing a series of spectra obtained at one hour intervals.

In order to ascertain that the spectra represented the metabolic activity of viable cells, iodoacetamide (0.1 mM), a respiratory poison was perfused through the cells and the change in metabolite profile observed. The cytotoxic effect of iodoacetamide caused a decline in β -ATP peak over the next ten hours. Furthermore, signal for extracellular Pi appeared immediately upon perfusion with iodoacetamide. The peak for extracellular peak increased with concomitant decrease in the intracellular peak for Pi, suggesting leakage of intracellular Pi into the extracellular space. The improved cell perfusion is stable for several days and is reliable for the study of cell metabolism in viable cells and for monitoring the effects of cytotoxic agents.

The U.S. Army Medical Research and Materiel Command under DAMD17-00-1-0291 supported this work.

APPENDIX 21

Abstract: Zhou, Y. and Sridhar, R. Interaction of tamoxifen with doxorubicin. Era of Hope. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume II, June 8-11, 2000, Atlanta, GA. pp 684.

INTERACTION OF TAMOXIFEN WITH DOXORUBICIN

Yanfei Zhou and Rajagopalan Sridhar

Howard University Cancer Center and Department of Radiation Oncology,
Washington, D.C. 20060

rsridhar@howard.edu

Doxorubicin (Adriamycin) is used alone or in combination with other drugs to treat metastatic breast cancer. Doxorubicin therapy is compromised by the development of a dose-limiting and potentially lethal cardiotoxicity. This may partly be due to free radical intermediates generated during metabolism of doxorubicin. The anti-estrogen tamoxifen protects biomembranes from free radical mediated oxidative damage. Tamoxifen has also shown some potential for reversing multidrug resistance in tumor cells. Ideally, the multidrug reversing agent should sensitize the tumor cells to the action of doxorubicin without any cardiotoxicity. Since cardiotoxicity may involve free radicals, it would be beneficial if the drug used to overcome drug resistance counteracted the free radical effects while potentiating the cytotoxicity of doxorubicin towards the tumor cells. Tamoxifen (10 μ M) partially inhibited NADPH dependent lipid peroxidation in rat heart and rat liver microsomes in the presence and absence of doxorubicin. The multidrug resistant human breast cancer cell line MCF7/ADR is nearly 100 times more resistant than the parental MCF7 cell line as judged by clonogenic assays of cultures treated with graded concentrations of doxorubicin. In this study, tamoxifen (10 μ M) treatment for 6 hours was toxic to both MCF7 and MCF7/ADR cells. Isobologram analysis revealed that combinations of tamoxifen and doxorubicin exhibited synergistic toxicity towards MCF7/ADR cultures, but exerted only additive effects against MCF7 cells. Both cell lines metabolized doxorubicin to the corresponding semiquinone free radical. Electron spin resonance (ESR) spectroscopy of cell suspensions treated with doxorubicin under anaerobic conditions at 37°C, demonstrated the formation of semiquinone free radical intermediate. Tamoxifen (10 μ M) did not affect the formation of the semiquinone radical in the incubation mixtures. Inclusion of the spin trap 5,5-dimethylpyrrolidine-N-oxide (DMPO) in aerated incubation mixtures containing cells and doxorubicin gave the hydroxyl spin adduct of DMPO. Comparison of free radical yields from MCF7 and MCF7/ADR cells in these experiments was difficult because the proportions of viable cells and doxorubicin concentrations could not be kept the same for both cell lines. Optimization of electron spin resonance experiments are in progress.

The U.S. Army Medical Research and Materiel Command under DAMD17-98-1-8109 supported this work.

APPENDIX 22

Abstract: Zhou, Y., Gu, X., Dhingra, S. and Sridhar, R. Nicotine inhibits doxorubicin-induced apoptosis of human breast cancer cells in culture. Department of Defense Breast Cancer Research Program Meeting. Proceedings Volume I, Abstract P10-25, September 25-28, 2002, Orlando, FL

NICOTINE INHIBITS DOXORUBICIN-INDUCED APOPTOSIS OF HUMAN BREAST CANCER CELLS IN CULTURE

Yanfei Zhou,¹ Xinbin Gu,¹ Sunny Dhingra,²
and Rajagopalan Sridhar¹

¹Cancer Center and Department of Radiation Oncology, and
²College of Dentistry, Howard University,
Washington, DC 20060

sridhar_howard@hotmail.com

In the United States approximately 7.5 % of cancer related deaths can be attributed to smoking¹. Use of tobacco after a cancer diagnosis decreases survival, promotes recurrence, field cancerization and decreases the efficacy of cancer therapy². The chemotherapeutic drug doxorubicin induces apoptosis in cancer cells. The effect of nicotine on doxorubicin-induced apoptosis was evaluated *in vitro* using MCF-7 human breast cancer cell cultures. Exponentially growing monolayer cultures of MCF-7 cells were treated with 20 μ M nicotine for 120 minutes, followed by a co-exposure to 10 μ M doxorubicin for 90 minutes. Apoptosis was assayed immediately after exposure to doxorubicin. Twenty micromolar nicotine inhibited doxorubicin-induced apoptosis, based on DNA fragmentation analysis, annexin V binding, and assays for caspase-3 and caspase-8 activities. Treatment with 10 μ M doxorubicin alone for 90 minutes increased caspase-3 activity to 142% and caspase-8 activity to 126% relative to 100% activity for each enzyme in untreated control cultures. However, a 2 hour pre-treatment with 20 μ M nicotine reduced the caspase-3 and caspase-8 activities respectively, in cultures treated with doxorubicin to 114% and 101% of control. This corresponds to a 20% inhibition of doxorubicin-induced apoptosis by 20 μ M nicotine in these cells. In a parallel set of experiments the drug containing medium was replaced with drug free medium after the 90 minute exposure to doxorubicin and then incubated at 37°C for 24 hours. When these cells were examined, inhibition of doxorubicin-induced apoptosis by nicotine could be demonstrated clearly using DNA fragmentation pattern, and annexin V binding, but not on the basis of caspase-3 and caspase-8 activities. Nicotine by itself had no effect on apoptosis, although it inhibited doxorubicin-induced apoptosis. Clonogenicity assays for viability also confirmed the ability of nicotine (10 and 20 μ M) to protect MCF-7 cells against the cytotoxicity of a 90 minute treatment with doxorubicin (1 and 10 μ M). Nicotine (10 and 20 μ M) did not affect the viability of MCF-7/ADR multidrug resistant cells treated with 10 μ M doxorubicin for 90 minutes. Inhibition of apoptosis in cancer cells by nicotine can diminish the effectiveness of doxorubicin in cancer therapy. Apoptosis is a defense mechanism against carcinogenesis. If nicotine inhibits apoptosis in normal cells or cells progressing towards malignancy, then the risk of secondary malignancies may be higher in patients who use tobacco products during and after doxorubicin treatment.

References: (1) Mortality trends for selected smoking-related cancers and breast cancer. United States 1950-1990. MMWR 1993; 42:857-863. (2) Schnoll RA *et al.* Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns. 2002 Feb;46(2):137-45.

Original work supported by the U.S. Army Medical Research and Materiel Command under DAMD17-98-1-8109.

P10-25

APPENDIX 23

Abstract: Sridhar, R., Balan, K.B., Shankar, R.A., Zhou, Y. and Goldson, A.L. Observations on the application of neutral red assay for cell viability. Abstract of presentation at EXPERIMENTAL BIOLOGY 2001, Orlando, FL, 2001. FASEB J. 15 (4): pp A238, 2001.

21214

Observations On The Application Of Neutral Red Assay For Cell Viability

Rajagopalan Sridhar, Kameswari Y Balan, Yanfei Zhou, Ravi A Shankar, Alfred L Goldson
Howard University, 2041 Georgia Ave., NW, Washington, DC 20060

The vital dye, neutral red is taken up by the lysosomes of viable but not dead cells. This is the basis of widely used neutral red assay for rapid screening of cytotoxic drugs. During investigations on the effects of hyperthermia on a panel of tumor cells several limitations of this assay were evident. In particular, cells killed by exposure to 43 degrees C for one hour did not differ appreciably from viable cells maintained at 37 degrees C with respect to neutral red uptake measured immediately after heat treatment. The cytotoxicity of the 43 degrees C treatment was confirmed using clonogenicity assays. If the neutral red uptake was measured after allowing the cells to grow for 48 hours after heat treatment some degree of killing could be demonstrated by the neutral red assay. The viability was higher when assayed by neutral red assay compared to clonogenicity measurements. In attempts to evaluate the response of multidrug resistant MCF-7/ADR cells it was found that they did not accumulate neutral red to the same extent as other drug sensitive cells, perhaps due to the operation of the drug efflux action of p-glycoprotein (pgp170). This made neutral red assay ineffective for measuring the viability of drug resistant MCF-7/ADR cells. It was also observed that uptake of neutral red by cells depended on the composition of the medium. For instance, the uptake was enhanced in Dulbecco's minimal essential medium (DMEM) containing 4.5 g/L glucose compared to DMEM with 1 g/L glucose. The pH of the medium also affected dye uptake by cells. Although time consuming, clonogenicity assays are superior to neutral red assay for cytotoxicity studies. (Supported in part by the U.S. Army Medical Research and Materiel Command under DAMD17-98-1-4109)

Review Article

Protein Kinases as Therapeutic Targets

Rajagopalan Sridhar,¹ Olivia Hanson-Printon,² and Denise R. Cooper^{3,4}

Received May 19, 2000; accepted July 14, 2000

Protein kinases and phosphatases are likely targets for the development of therapeutic drugs since they are involved in specific signaling pathways which regulate cell functions such as metabolism, cell cycle progression, cell adhesion, vascular function and angiogenesis. Protein phosphorylation and dephosphorylation serve as molecular switches for modulating these processes and the level and duration of each is a highly regulated process in normal cells. Several compounds that inhibit the activity of tyrosine kinases are being evaluated as cancer therapeutic agents in clinical trials. Diabetes and complications of diabetes also involve deregulated levels of protein kinases. New approaches for regulating kinase gene expression include specific antisense oligonucleotides for inhibiting post-transcriptional processing of the messenger RNA, naturally occurring products and their chemical derivatives to inhibit kinase activity, and monoclonal antibodies to inhibit receptor linked kinases. Inhibition of phosphatases also serves to alter the duration of phosphorylation by kinases. Considerations for development of effective inhibitors include non-specific actions of compounds, cellular uptake, multiple intracellular targets that can dilute the effective cellular concentration of an agent, and tissue specificity. Kinase inhibitors may allow other therapeutic agents additional time to become effective and they may act synergistically with current treatments.

KEY WORDS: protein kinase; signal transduction; drug design; chemotherapeutic agents.

Eukaryotic protein kinases constitute a large family of homologous proteins that catalyze the transfer of the gamma phosphate group of ATP or GTP to the hydroxyl group of serine, threonine or tyrosine in a substrate protein. Protein kinases differ in structure, subcellular location, substrate specificity, and function. Cellular signaling cascades rely on the phosphorylation status of pathway proteins to alter their function. Some substrates transmit the signal, while the final protein targets are altered in activity. Phosphorylated serine, threonine, or tyrosine residues are substrates for specific protein phosphatases so that phosphorylation and dephosphorylation serve as molecular switches and each is highly regulated as to level and duration (Figure 1) (1-4).

Cellular functions such as gene expression, cytoskeletal integrity, cell adhesion, cell cycle progression, and differentiation are controlled by the complex interplay of protein kinases and phosphatases in specific signaling pathways (5-12). Malfunctions of cellular signaling have been associated with many diseases including cancer and diabetes. Regulation

of signal transduction by cytokines and the association of signal molecules with protooncogenes and tumor suppressor genes have been subjects of intense research in the industrial setting as well as in academics. Many therapeutic strategies can now be developed through the synthesis of compounds which activate or inactivate protein kinases. In a multicellular organism, intercellular communication plays a crucial role under normal as well as pathological conditions. Coexistence of abnormal cells with normal cells provide the stroma and blood supply essential for maintaining growth and progression of tumors. Such codependence relies on a wide array of receptors and signal transduction pathways to the nucleus of either the host or cancer cell. Since aberrant expression/activation of protein kinase C appears to be involved in the development of certain types of cancer, diabetes and complications of diabetes, the search for selective PKC inhibitors is a major goal of many researchers. Mutant tyrosine kinases are also often associated with carcinogenesis in certain organs, making tyrosine kinase signaling pathways attractive targets for oncology research.

Cytokines, hormones and growth factors bind and activate specific receptors. The molecular mechanisms of signal transduction pathways were elucidated by identifying the specific protein kinase cascades along with their downstream targets, which include some specific transcription factors. Protein kinases act in concert with cytokines, cell cycle regulatory molecules, proteins of apoptotic machinery and transcription factors via pathways that regulate cell metabolism, differentiation, proliferation and death. Many therapeutic strategies are aimed at critical components in signal transduction pathways (9-13).

¹ Department of Radiation Oncology, Howard University Hospital and Cancer Center, Washington, D.C.

² Department of Chemistry, University of Central Oklahoma, Edmond, OK.

³ J. A. Haley Veterans Hospital and Departments of Biochemistry and Molecular Biology and Medicine, University of South Florida College of Medicine, Tampa, FL.

⁴ To whom correspondence should be addressed at J.A. Haley Veterans Hospital, 13000 Bruce B. Downs Blvd, Tampa, FL 33612. (e-mail: dcooper@csm1.med.usf.edu)




Fig. 1. Kinases and phosphatases provide molecular switches for altering protein function. Protein phosphorylation is a post-translational modification in cells that is reversible by the action of phosphatases. It is one of the most important mechanisms used by cells for signal transduction.

PROTEIN KINASES ARE GROUPED FUNCTIONALLY

Eukaryotic protein kinases typically encode a 250 amino acid catalytic domain that is commonly under the control of a separate regulatory domain or subunit. Hanks and Hunter

have classified them on the basis of their structural and functional properties (14). The protein kinase "phylogenetic tree" (Figure 2) was derived from aligning kinase domain amino acid sequences (14). There are five kinase categories: 1) the cyclic nucleotide-regulated and phospholipid-regulated kinases and ribosomal S6 kinases (AGC), 2) the Ca^{2+} /calmodulin kinases (CaMK), 3) the cyclin-dependent kinases (CMGC), 4) the protein tyrosine kinases (PTK), and 5) "other" kinases falling outside the four major groups. Members of groups share substrate preferences. For example, both the AGC and CaMK groups phosphorylate serine/threonine residues near arginine and/or lysine. Members of the serine/threonine kinase group, CMGC, phosphorylate serine/threonine in proline-rich domains. The CMGC kinases have larger catalytic domains than other kinases. The PTK group includes both receptor and non-receptor kinases that phosphorylate tyrosine residues. Other kinases can phosphorylate either serine/threonine and tyrosine residues and some are termed dual-specificity kinases. The cellular function of many kinases was elucidated initially by broad specificity inhibitors. With the rapid expansion of DNA sequence databases, it is likely that additional kinases will be discovered.

Group:

Family:




Fig. 2. Diagram of the major families of protein kinases. Kinase catalytic domains are shaded black. The AGC group includes cyclic nucleotide-dependent protein kinases (Protein kinase A (PKA) and Protein kinase G (PKG)) and lipid-dependent protein kinase C (PKC) families. The catalytic subunit of PKA is shown. PKG contains a cGMP binding domain which is shaded gray. The regulatory domain of PKC is also shaded gray. The CaMK group shows the shaded autoregulatory domain (site that binds Ca^{2+} /calmodulin). The CMGC group includes the CDK, MAPK/ERK and GSK-3 families. The PTK group includes the Src family and the EGFR RTK family. The N-terminal myristoyl (Myr) modification allows for membrane attachment. The SH2 and SH3 domains are shown. RTKs contain transmembrane (TM) and extracellular binding domains for ligands (checked shading). The "other" group includes MEK, Raf, and the TGF- β receptor and LIM kinases. Raf kinases have a Ras binding domain (RBD). The TGF- β receptors have extracellular ligand binding domains (checked shading) and TM domains. The LIM and PDZ domains are noted in LIMK.

DEPHOSPHORYLATION BY PROTEIN PHOSPHATASES

Dephosphorylation by protein phosphatases plays an equally important role in regulating cellular processes. Protein phosphatases have specificities that are as distinct as those of the protein kinases, and a similar number of genes encode both family members (15,16). They are classified based on substrate specificity, dependence on metal ions, and sensitivity to inhibitory agents. Table 1 summarizes the distribution and known inhibitors of protein phosphatases which have been demonstrated to play a role in signal transduction. They possess a 230 amino acid catalytic domain and contain a number of regulatory subunits that govern subcellular localization and enzymatic activity (15,20). The activities of PP1 and PP2A are independent of metal ions (15,16). The catalytic subunit of PP1 binds to regulatory subunits that determine PP1 subcellular localization and activity (17) while PP2A is inactivated by transient phosphorylation of tyrosine residues on the molecule (18). PP2B, also known as calcineurin, consists of a catalytic subunit (A-subunit, 6kDa) and a regulatory subunit (B-subunit, 19kDa). It is dependent on the Ca^{2+} -calmodulin complex for complete activation (19). Over 40 protein tyrosine phosphatases (PTP) have been characterized. Specific activators of protein phosphatases are still being sought. The C2, C6 and C16 ceramides are reported activators of protein phosphatases (21-23).

THERAPEUTIC STRATEGIES FOR TREATING CANCER

Cancer treatment strategies include: (i) inhibiting tumor cell proliferation, (ii) inducing tumor cell death by necrosis or apoptosis, (iii) inhibiting tumor angiogenesis, (iv) facilitating host immune system, (v) inducing vegetative tumor cells to undergo terminal differentiation, (vi) inhibiting metastases by inhibiting tumor cell adhesion and invasiveness of normal tissues.

Table 1. Protein Phosphatases Involved in Signal Transduction

| Protein phosphatase type | Subcellular distribution | Known inhibitors |
|--------------------------|--------------------------|------------------------|
| PP1 | Cytosol | Calyculin A |
| | Nucleus | Nodularin |
| | Myofibrils | Tautomycin |
| | Glycogen particles | |
| PP2A | Cytosol | Calyculins |
| | Nucleus | Microcystins |
| | Mitochondria | Nodularin |
| | | Okadaic acid |
| PP2B (calcineurin) | Cytosol | Cyclosporin A |
| | Nucleus | FK506 |
| | Plasma membrane | Immunophilin complexes |
| | Synaptosomes | Cypermethrin |
| | | Deltamethrin |
| PTP | Plasma membrane | Penicillate |
| | Nucleus | bp V(phen) |
| | | mpV(pic) |
| | | Dephosphatins |
| | | Phenylarsine Oxide |
| | | Sodium Orthovanadate |

TYROSINE KINASES AS THERAPEUTIC TARGETS FOR CANCER CHEMOTHERAPY

Recent efforts in drug design have targeted specific kinases. Ras is one of the most frequently mutated oncogenes in human cancers (24,25), and Ras signaling is a downstream event of tyrosine kinase activation. Therefore modifiers of tyrosine kinases are actively being investigated as anti-cancer drugs. Cytoplasmic tyrosine kinases frequently contain SH2 and SH3 domains (src Homology 2 and 3 domains) which mediate intra- and interprotein interactions (Figure 2). SH2 domains bind to phosphotyrosine sites with flanking amino acids that are specific for the particular SH2 sequence, and SH3 domains latch on to proline-rich regions (10).

Receptor tyrosine kinases (RTKs), many of which are growth factor receptors, are transmembrane glycoproteins with a membrane spanning domain and a conserved cytoplasmic tyrosine kinase domain. The RTK superfamily consists of 18 families in vertebrates and includes 56 different receptors including insulin, fibroblast growth factor (FGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and vascular endothelial growth factor (VEGF), and many other receptors.

There is considerable structural similarity among each RTK subfamily. Related receptors usually bind related ligands such as the HER family of receptors (EGF receptor, HER2, HER3 and HER 4) and their ligands (TGF- α), amphiregulin, heparin binding EGF (HB-EGF), betacellulin, and heregulin. Each of these receptors contains two domains that share the conserved sequence pattern of nearly 50 cysteine residues; additionally, each of the ligands contains a conserved motif of cysteine sextet present in the prototypical EGF (10).

Binding of a ligand to an RTK leads to receptor dimerization and activation of the intracellular catalytic (kinase) domain. In the dimer, the catalytic unit of one receptor subunit phosphorylates specific tyrosines in the other subunit. The phosphorylated receptors then phosphorylate or interact with other adapter and signaling molecules through phosphotyrosines, triggering a cascade of further phosphorylations and/or dephosphorylations. After a series of downstream events involving several proteins, the signal reaches the nucleus in the form of a molecule which can alter the activity of the genetic machinery to control cell proliferation, differentiation, cell metabolism, and even programmed cell death (apoptosis) (10,26,27).

Insulin-like growth factor 1 (IGF-1) and related receptors exist as preformed dimers of α and β chains. Following activation, the ligand-induced phosphorylation is similar to the RTK pathway. The phosphotyrosines of the receptor can bind to an adapter molecule or substrate such as phosphatidylinositol (PI) 3-kinase. The association of PI-3-kinase with the intracellular domain of phosphorylated RTK enhances PI-3 kinase activity via allosteric activation of the catalytic subunit (10,28). In contrast to substrates of RTKs such as PI-3-kinase, the adapter molecules contain no intrinsic catalytic activity. An example of an adapter molecule in this signaling is Grb2 in the MAP kinase pathway (29).

There is strong evidence for the involvement of RTKs in human cancer making these a target for inhibition (10,30). Examples of these are *erbB* (EGF receptor), *neu* (HER2), *kii*

(stem-cell factor receptor), *fms* (CSF1 receptor), *met* (HGF receptor), *trk* (neurotrophin receptor), *sea*, *ros*, *ret*, *eyk*, and *axl* (10). A number of cytoplasmic tyrosine kinases including *src* and *abl* behave as oncogenes when mutated or inappropriately expressed (10). Nearly 30% of human breast and ovarian cancers show amplified expression of the receptor tyrosine kinase HER2 (31). Amplification of HER2 gene also correlates with decreased patient survival and a shorter time for recurrence of disease (32).

Blocking of the receptor/ligand interaction is also an effective therapeutic target. Herceptin (Genentech, San Francisco, CA) is a humanized monoclonal antibody against HER2. The success of Herceptin in cancer treatment supports the hypothesis that blocking certain RTKs can curtail cancer progression. Alteration or overexpression of RTKs such as PDGF and EGF receptors has also been associated with certain cancers. Inhibitors of RTKs may inhibit the growth and proliferation of such cancers, since RTKs stimulate tumor cell proliferation.

Inhibitors of RTKs are useful in preventing tumor angiogenesis and can eliminate support from the host tissue by targeting RTKs located on vascular cells (e.g., blood vessel endothelial cells and stromal fibroblasts (FGF receptor)). Another example of restricting blood supply to a tumor could be through vascular endothelial growth factor (VEGF) and its receptor. Several splice variants of VEGF are known (e.g., VEGF₁₂₁, VEGF₁₆₅, VEGF₁₈₉, VEGF₂₀₆) which vary in the number of amino acids in the peptide (33). VEGF stimulates endothelial cell growth during angiogenesis, and increases the permeability of tumor vasculature so that proteins and other growth factors become accessible to the tumor (10). Broad-spectrum antitumor efficacy of an oral dosage form of an inhibitor of VEGF signaling has been reported (33). Thus, inhibition of VEGF receptor signaling presents an important therapeutic target. An extracellular receptor can also be a target for inhibition. For example, the EGF receptor family and its ligands are overexpressed and exist as an autocrine loop in many tumor types. One EGF-related peptide, amphiregulin, is coexpressed in pancreatic and ovarian cancer (10). HB-EGF is expressed as an autocrine loop in gastric cancer.

EGF receptor is found in over half of breast tumors unresponsive to hormone (10). EGF is found in many tumors, and EGF may be required for tumor cell growth. Antibody to EGF blocked the growth of tumor xenografts in mice (35). An antisense oligonucleotide for amphiregulin inhibited growth of a pancreatic cancer cell line (36). A variety of inhibitors of RTKs are listed in Table 2, some of which are already in clinical trials.

OTHER TARGET POSSIBILITIES

Many tyrosine kinase inhibitors are derived from natural products including flavopiridol, genistein, erbstatin, lavendustin A, staurosporine, and UCN-01. Inhibitors directed at the ATP binding site are also available (11,37). Signals from RTKs can also be inhibited at other target sites such as: nuclear tyrosine kinases, membrane anchors (inhibition of farnesylation) and transcription factors.

DEFINING THE TARGET

Targeting the signaling potential of growth promoting tyrosine kinases such as EGFR, HER2, PDGFR, *src*, and *abl*, will block tumor growth while blocking IGF-1 and TRK will interfere with tumor cell survival. Inhibiting these kinases will lead to tumor shrinkage and apoptosis. Flk-1/KDR and *src* are kinases necessary for neovascularization (angiogenesis) of tumors and inhibition of these will slow tumor growth thereby decreasing metastases (38). *Met* promotes cell migration, and inhibiting this kinase should also decrease metastases (39).

The usual criteria applicable for evaluating conventional chemotherapy drugs may fail to detect the efficacy of drugs targeted against RTKs. Inhibitors of RTKs stabilize the tumor in terms of cell proliferation, normal cell loss via apoptosis, and prevent cell migration, invasion and metastases. These drugs are likely to increase the time required for tumor progression, and may inhibit or attenuate the aggressiveness of the disease but may not initially result in measurable tumor regression. Therefore, specially designed trials are needed to evaluate the usefulness of drugs designed for RTK inhibi-

Table 2. Inhibitors of Receptor Tyrosine Kinases

| Inhibitor | Tyrosine kinase target | Clinical trial | Source |
|---------------------|------------------------|--|--------------|
| Genistein | EGF-R, v-src | | |
| Herbimycin A | EGF-R | | |
| HNMPA-(AM)3 | IR-K | | |
| Lavendustin A | IR-K | | |
| Tyrphostin 23 | IR-K, EFG-R | | |
| PP1 | v-src | | Pfizer |
| PP2 | v-src | | Pfizer |
| ZD 1839 (Iressa™) | EGF-R | Phase I (NSCLC, breast, colorectal, ovarian, renal, esophageal, pancreatic, and mesothelioma solid tumors) | Zeneca |
| CP-358774 | EGF-R | | Pfizer |
| CGP 59326 | EGF-R | | Novartis |
| PD 166285 | EGF-R, PDGF-R, v-src | | Parke-Davis |
| CGP 57148 | PDGF-R | | Novartis |
| SU101 (Leflunomide) | PDGF-R | Phase III (glioblastoma multiform) and Phase II (prostate, lung and ovarian cancer) | Sugen |
| SU 5416 | Flk-1/KDR | Phase II (AIDS-related Kaposi sarcoma) | Sugen |
| STI 571 | abl | Phase I (Philadelphia-chromosome-positive leukemia) | Novartis |
| ZD4190 | VEGF-R | | Astra Zeneca |

tion. Perhaps drugs will act synergistically with the currently utilized chemotherapeutic agents. Inhibitors of RTKs are less likely to have adverse systemic toxicity since they are cytostatic and not cytotoxic. They are likely to delay tumor progression by inhibiting cell cycle transit allowing other therapeutic agents additional time to cause tumor regression.

An example of cancer arising from a defective tyrosine kinase is a class of ALK positive lymphomas referred to as "ALKomas" which display inappropriate expression of a neural-specific tyrosine kinase, anaplastic lymphoma kinase (ALK) (40). Many solid tumors overexpress epidermal growth factor receptor (41). Iressa (ZD1839) is an orally active selective EGF-R inhibitor. This compound disrupts signaling involved in cancer cell proliferation, cell survival and tumor growth support by the host (42). The clinical efficacy of this agent shows that it is well tolerated by patients undergoing Phase I/II clinical trials (43,44). The compound has shown promising cytotoxicity towards several cancer cell lines (43).

Many growth factors and cytokines regulate cellular functions via the Janus kinase (JAK) signal transducers and activators of transcription (STAT). Membrane-associated JAK tyrosine kinases are activated upon ligand binding to an RTK. This preferentially recruits dormant cytoplasmic transcription factors (STATs) which are subsequently activated by phosphorylation. The phosphorylated STATs migrate to the nucleus and activate transcription of the target gene (45,46). Cells derived from rat and human cancers have constitutively activated Stat3, and the malignant potential of cancer has been associated with Stat3 activation (47,48). The JAK inhibitor AG940 prevents Stat3 activation and suppresses the growth of human prostate cancer cells (48).

DNA DEPENDENT PROTEIN KINASES

DNA-dependent protein kinase (DNA-PK) is involved in the repair of double-strand breaks in mammalian cells. This enzyme requires ends of double stranded DNA or transitions from single stranded to double stranded DNA in order to act as a serine/threonine kinase (49-54). Cells with defective or deficient DNA-PK activity are unable to repair radiation induced DNA double strand breaks and consequently very sensitive to the lethal effects of ionizing radiation (50-53). DNA-PK dependent repair of DNA double strand break involves DNA ligase IV and XRCC4 (53-55). Inhibition of DNA-PK has the potential to increase the efficacy of antitumor treatment with radiation or chemotherapeutic agents.

CELL CYCLE REGULATION BY CYCLIN DEPENDENT KINASES

Progression through the cell cycle is controlled in part by a series of regulatory molecules called cyclins and the cyclin-dependent kinases (CDK) which they activate. In addition to the cyclins, CDK activity is also regulated by phosphorylation and dephosphorylation. Cellular inhibitors of CDKs also play a major role in cell cycle progression (56). Alterations in the expression, function, and structure of cyclin and CDK are encountered in the cancer phenotype. Therefore CDKs may be important targets for new cancer therapeutic agents. Cell cycle perturbations occur in tumors and tumor cells treated with ionizing radiation and/or chemotherapeutic agents.

Whether or not the DNA damage caused in cells leads to cell death depends on normal cell cycle control mechanisms that are in place. Often chemotherapy resistant cells tend to escape apoptosis. Under certain circumstances, inappropriate CDK activation may even promote apoptosis by encouraging the progression of the cell cycle under unfavorable conditions, i.e., attempting mitosis while DNA damage is largely unrepaired.

INHIBITION OF CDKs TO INDUCE APOPTOSIS IN CANCER CELLS

Purines and purine analogs act as CDK inhibitors. Flavopiridol (L86-8275) is a flavonoid that causes 50% growth inhibition of tumor cells at 60 nM (57). It also inhibits EGFR and protein kinase A (IC_{50} about 100 μ M) (57). Flavopiridol induces apoptosis and inhibits lymphoid, myeloid, colon, and prostate cancer cells grown *in vivo* as tumor xenografts in nude mice. At the molecular level, flavopiridol affects CDK function and arrests cells in the G₂/M and G₁/S border. Both cycling and non-cycling cells are killed by flavopiridol. At concentrations above 1 micromolar, flavopiridol loses its selectivity and starts inhibiting other kinases (e.g., 6 μ M is the IC_{50} for protein kinase C) (57). Staurosporine and its derivative, UCN-01, in addition to inhibiting protein kinase C, inhibit cyclin B/CDK (IC_{50} 3 to 5 nM). Staurosporine is toxic, but its derivative 7-hydroxystaurosporine (UCN-01) has antitumor properties and is in clinical trials (58). UCN-01 affects the phosphorylation of CDKs and alters the cell cycle checkpoint functioning. These compounds illustrate that multiple intracellular targets may be affected as the concentration of an inhibitor is increased within cells.

TISSUE SPECIFICITY AS A COMPONENT OF IDENTIFYING THE THERAPEUTIC TARGET

Tamoxifen, a protein kinase C inhibitor with anti-estrogen activity, is currently a standard treatment for hormone-dependent breast cancer. The use of this compound may increase the risk of developing cancer in other tissues such as the endometrium (59). Raloxifene, a related compound, has been shown to protect against osteoporosis (59). The tissue specificity of inhibitors must be considered when identifying therapeutic targets.

MITOGEN ACTIVATED KINASE (MAP KINASES) IN CARCINOGENESIS

Signal transduction to the nucleus in response to extracellular stimulus by a growth factor involves the mitogen-activated protein (MAP) kinases. MAP kinases are a family of protein serine/threonine kinases which mediate signal transduction from extracellular receptors or heat shock, or UV radiation (some receptors are tyrosine kinase receptors) (60,61). These kinases, in concert with other signal transduction pathways can network to differentially alter the phosphorylation of transcription factors. Cell proliferation and differentiation in normal cells are under the regulation and control of multiple MAP kinase cascades. Aberrant and deregulated functioning of MAP kinases can initiate and support carcinogenesis (62,63). Insulin and IGF-1 also activate a mitogenic MAP kinase pathway that may be important in

acquired insulin resistance occurring in type 2 diabetes (64).

PHOSPHATIDYLINOSITOL 3-KINASE, PKB/AKT AND CELL SURVIVAL

Many cancers become refractory to chemotherapy by developing a survival strategy involving the constitutive activation of the phosphatidylinositol 3-kinase-protein kinase B/Akt signaling cascade. This survival signaling pathway thus becomes an important target for the development of specific inhibitors that would block its function (65-68). PI-3 kinase/Akt signaling is equally important in diabetes (69). The pathway activated by RTKs subsequently regulates glycogen synthase kinase 3 (GSK3) and glucose uptake. Since Akt has decreased activity in type 2 diabetes, it provides a therapeutic target (69).

KINASE INHIBITORS AS TOOLS FOR STUDYING CELLULAR SIGNALING

Protein kinase inhibitors provide much of our knowledge about regulation and coordination of physiological functions. Endogenous peptide inhibitors occur *in vivo* (70). A pseudosubstrate sequence within PKC acts to inhibit the kinase in the absence of its lipid activator (71). A PKC inhibitor such as chelerythrine acts on the catalytic domain to block substrate interaction, while calphostin C acts on the regulatory domain to mimic the pseudosubstrate sequence and block ATPase activity, or by inhibiting cofactor binding. The ability to inhibit specific PKC isozymes is limited. The most specific inhibitors appear to be directed toward the conventional PKCs (regulated by phospholipids, calcium, and diacylglycerol) with

at least two inhibitors of PKC β identified (72,73). Most PKC inhibitors, including those for PKC β , inhibit insulin-induced glucose uptake (73,78). The importance of PKC activation for insulin action has been the topic of numerous studies. Multiple PKC isozymes appear to be involved in regulating glucose uptake (78) and insulin resistance mediated by the insulin receptor (79).

The caveat for evaluating the specific function of a kinase using inhibitors lies in the non-specific actions of some compounds and their ability to inhibit a number of different protein kinases or, at higher concentrations, similar isozymes. The cellular uptake, half-life, diffusion, or multiple intracellular receptors are also considerations when interpreting inhibitor effects on metabolic and mitogenic function.

Activated kinases can have multiple substrates that are then trafficked to subcellular locations via phosphorylation/dephosphorylation signals. Nuclear targets of activated kinases are thought to be transcriptional activation factors. Another mechanism of activating transcription factors that are dormant in the cytoplasm is their translocation into the nucleus upon phosphorylation. This mechanism of signal transduction is observed in the case of NF- κ B proteins (74). NF- κ B complexes are inactive due to complexing with I κ B inhibitors, but upon phosphorylation of the regulatory I κ B by PKC and PKA, free NF- κ B complexes are dissociated and are then translocated to the nucleus (74).

OTHER MODES OF REGULATING PROTEIN KINASES

Although some protein kinases have, to date, no known system of physiological regulation, many are activated or in-




Fig. 3. Regulatory control points in gene expression by growth factors. Protein kinase signaling pathways activated by protein tyrosine kinases are known to regulate RNA transcription, post-transcriptional processing of pre-mRNA, mRNA stability, and protein phosphorylation.

activated by autophosphorylation or phosphorylation by upstream protein kinases. The regulation of protein kinases also occurs transcriptionally, post-transcriptionally, and post-translationally (Figure 3). The mechanism of post-transcriptional regulation is alternative splicing of precursor mRNA (75). Protein kinase C- β I and - β II are two isoforms of a single PKC β gene derived from differences in the splicing of the exon encoding the C-terminal 50–52 amino acids. Splicing can be regulated by a kinase cascade in response to peptide hormones such as insulin and IGF-1 (75). PKC β I and β II have different specificities for phosphorylating members of the mitogen activated protein (MAP) kinase family, for glycogen synthase 3 β , for nuclear transcription factors such as TLS/Fus, and for other nuclear kinases (76–78). By inhibiting the post-transcriptional alternative splicing of PKC β II mRNA, PKC β II-dependent processes are inhibited.

The stability of mRNA encoding the PKC isozymes is also apparently regulated by kinase cascades. Destabilization of PKC δ mRNA by phorbol esters is one example (80). The destabilization of PKC β II mRNA by glucose is another case in which stability is modulated by protein kinases (81). Thus, regulation of PKC β II expression by insulin via alternative splicing of pre-mRNA and glucose via destabilization of mRNA, suggests that post-transcriptional processing may be a likely target for altering kinase levels. The development of antisense oligonucleotides to inhibit the expression of various protein kinases has been successful. Antisense oligonucleotides are short lengths of synthetically manufactured, chemically modified DNA or RNA designed to specifically interact with mRNA transcripts encoding target proteins. The interaction of the antisense moiety with mRNA inhibits protein translation and, in some cases, post-transcriptional processing (e.g., alternative splicing and stability) of mRNA. Antisense oligonucleotides have been developed to alter alternative splicing of BclX long to short mRNA forms and for inhibiting the translation of PKC α and PKC ζ (82).

PROTEIN KINASE INHIBITORS IN CARDIOVASCULAR DISEASE AND VASCULAR COMPLICATIONS IN DIABETES MELLITUS

Protein kinase C isoforms have been implicated in cellular changes observed in the vascular complications of diabetes. Hyperglycemia is associated with increased levels of PKC α and β isoforms in renal glomeruli of diabetic rats (72). Oral administration of a PKC β inhibitor prevented the increased mRNA expression of TGF- β I and extracellular matrix component genes (72). Administration of the specific PKC β inhibitor (LY333531) also normalized levels of cytokines, caldesmon and hemodynamics of retinal and renal blood flow (72). Overexpression of the PKC β isoform in the myocardium resulted in cardiac hypertrophy and failure (72). The use of LY333531 to prevent adverse effects of cardiac PKC β overexpression in diabetic subjects is under investigation (72). The compound is also in Phase II/III clinical trials for diabetic retinopathy and diabetic macular edema indicating that it may be pharmacodynamically active (83).

CONCLUSIONS

Our original understanding of kinases and their roles in cellular metabolism are based on work by Krebs, Graves and

Fisher (84), more recently, information provided from investigations on such diverse species as *D. melanogaster*, *S. cerevisiae*, *D. discoideum*, and *C. elegans* has identified new kinase genes and allowed cloning of their mammalian counterparts (1,3). The further use of peptide libraries, protein-RNA, protein-DNA, and protein-protein interaction systems will advance our understanding of kinase specificity and how kinases are regulated by protein interaction, and will provide additional molecular possibilities for drug intervention.

ACKNOWLEDGMENTS

This work was supported by the Medical Research Service of the Department of Veterans Affairs (D.R.C.), American Heart Association-Florida/Puerto Rico Affiliate (D.R.C.), the National Science Foundation (D.R.C.), Grant #DAMD17-98-1-8109 from the Department of Defense (R.S.), and Cooperative Agreement #NCC8-184 with N.A.S.A. (R.S.).


REFERENCES

1. T. Hunter and G. D. Flawman. The protein kinases of budding yeast: Six score and more. *Trends Biochem. Sci.* 22:18–22 (1997).
2. T. Hunter. 1001 protein kinases redux: Towards 2000. *Semin. Cell Biol.* 5:367–376 (1994).
3. G. Hardie and S. Hanks. The eukaryotic protein kinase superfamily. In G. Hardie and S. Hanks (eds.), *The Protein Kinase Facts Book*, Acad. Press, London, Vol. 1, Chap. 2, 1995 pp. 7–47.
4. T. Pawson. Protein molecules and signaling networks. *Nature* 373: 573–580 (1995).
5. G. L. King, H. Ishii, and D. Koya. Diabetic vascular dysfunction: A model of excessive activation of protein kinase C. *Kidney Int. Suppl.* 66:S77–S85 (1997).
6. I. K. Klein, S. R. Rilland, L. J. Burgart, S. C. Ziesmer, P. C. Roche, S. J. Gendler, and W. E. Kames, Jr. Adenoma-specific alterations of protein kinase C isozyme expression in *Apc^{min}* mice. *Cancer Res.* 60:2077–2080 (2000).
7. L. A. Davidson, C. M. Aymond, Y. H. Jiang, N. D. Turner, J. R. Lupton, and R. S. Chapkin. Non-invasive detection of fecal protein kinase C β II and ζ messenger RNA: Putative biomarkers for colon cancer. *Carcinogenesis (Lond)* 19:253–257 (1998).
8. F. Marks and M. Geschwendt. Protein kinase C in disease. In F. Mark (ed.), *Protein phosphorylation*, VCH, Weinheim, Chap. 3.4, 1996 pp. 101–108.
9. A. Levitzki and A. Gazit. Tyrosine kinase inhibition: an approach to drug development. *Science* 267:1782–1788 (1995).
10. L. Shawver. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development. In M. C. Perry (ed.) *American Society of Clinical Oncology Educational Book*, American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA, pp. 29–47 (1999).
11. E. Sausville. Cyclin-dependent kinases: Novel targets for cancer treatment. In M. C. Perry (ed.) *American Society of Clinical Oncology Educational Book*, American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA, pp. 9–21 (1999).
12. W. L. Blalock, C. Weinstein-Oppenheim, F. Chang, P. E. Hoyte, X.-Y. Wang, P. A. Algate, R. A. Franklin, S. M. Oberhaus, L. S. Steelman, and J. A. McCubrey. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. *Leukemia* 13:1109–1166 (1999).
13. R. Caliceti-Falcone, W. S. Dalton, and R. Jove. STAT proteins as novel targets for cancer therapy. *Curr. Opin. in. Oncology* 11: 490–496 (1999).
14. S. K. Hanks and T. Hunter. Protein kinases: The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. *FASEB J* 9:576–596 (1995).
15. L. Li and J. E. Dixon. Form, function, and regulation of protein

- tyrosine phosphatases and their involvement in human diseases. *Semin. Immunol.* 12:75-84 (2000).
16. M. C. Mumby and G. Walter. Protein serine/threonine phosphatases: Structure, regulation, and functions in cell growth. *Physiol. Rev.* 73:673-699 (1993).
 17. M. J. Hubbard and P. Cohen. On target with a new mechanism for the regulation of protein phosphorylation. *Trends Biochem. Sci.* 18:172-177 (1993).
 18. J. Chen, S. Parsons, and D. L. Brautigan. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. *J. Biol. Chem.* 269:7957-7962 (1994).
 19. T. Hunter. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. *Cell* 80:225-236 (1995).
 20. L. J. Mauro and J. E. Dixon. 'Zip codes' direct intracellular protein tyrosine phosphatases to the correct cellular 'address'. *Trends Biochem. Sci.* 19:151-155 (1994).
 21. J. K. Westwick, A. E. Bielawska, G. Dbaibo, Y. A. Hannun, and D. A. Brenner. Ceramide activates the stress-activated protein kinases. *J. Biol. Chem.* 270:22689-22692 (1995).
 22. S. Jayadev, B. Liu, A. E. Bielawska, J. Y. Lee, F. Nazaire, M. Y. Pushkareva, L. M. Obeid, and Y. A. Hannun. Role for ceramide in cell cycle arrest. *J. Biol. Chem.* 270:2047-2052 (1995).
 23. S. Mathias, K. A. Dressler, and R. N. Kolesnick. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha. *Proc. Natl. Acad. Sci. USA* 88:10009-10015 (1991).
 24. A. Cuadrado, J. T. Bruder, M. A. Heidaran, H. App, U. R. Rapp, and S. A. Aaronson. H-Ras and Raf-1 cooperate in the transformation of NIH3T3 fibroblasts. *Oncogene* 8:2443-2448 (1993).
 25. R. Saez, A. M. Chan, T. Miki, and S. A. Aaronson. Oncogenic activation of human R-Ras by point mutations analogous to those of prototype H-Ras oncogenes. *Oncogene* 9:2977-2982 (1994).
 26. T. Hunter. Oncoprotein networks. *Cell* 88:333-346 (1997).
 27. A. Ullrich and J. Schlessinger. Signal transduction by receptors with tyrosine kinase activity. *Cell* 61:203-212 (1990).
 28. C. L. Carpenter and L. C. Cantley. Phosphoinositide kinases. *Curr. Opin. Cell Biol.* 8:153-158 (1996).
 29. P. W. Schenk and B. E. Snaar-Jagalska. Signal perception and transduction: The role of protein kinases. *Biochim. Biophys. Acta* 1449:1-24 (1999).
 30. J. S. Ross and J. A. Fletcher. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, a target for therapy. *Stem Cells* 16:413-428 (1998).
 31. D. M. Reese and D. J. Slamon. HER2/neu signal transduction in human breast and ovarian cancer. *Stem Cells* 15:1-8 (1997).
 32. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. *Science* 235:177-182 (1987).
 33. S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. Stokes, B. Curry, G. H. Richmond, and P. F. Wadsworth. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad spectrum antitumor efficacy. *Cancer Res.* 60:970-975 (2000).
 34. H. Masui, T. Kawamoto, J. D. Sato, B. Wolf, G. Sato, and J. Mendelsohn. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. *Cancer Res.* 44:1002-1007 (1984).
 35. H. Funatomi, J. Itakura, T. Ishitawa, I. Pastan, S. A. Thompson, G. R. Johnson, and M. Korc. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor targeted therapy. *Int. J. Cancer* 72:512-517 (1997).
 36. N. S. Gray, L. Wodicka, A. M. Thunnissen, T. C. Norman, S. Kwon, F. H. Espinoza, D. O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S. J. Kim, D. J. Lockhart, and P. G. Schultz. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. *Science* 281:533-538 (1998).
 37. L. Tong, S. Pav, D. M. White, S. Rogers, K. M. Crane, C. L. Cywin, M. L. Brown, and C. A. Pargellis. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. *Nature Struct. Biol.* 4:311 (1997).
 38. L. M. Strawn, G. McMahon, H. App, R. Schreck, W. R. Kuchler, M. P. Longhi, T. H. Jui, C. Tang, A. Levitzki, A. Gazit, I. Chen, G. Keri, L. Orfi, W. Risau, I. Flamme, A. Ullrich, K. P. Hirth, and L. K. Shawver. Flk-1 as a target for tumor growth inhibition. *Cancer Res.* 56:3540-3545 (1996).
 39. M. Jeffers, M. Fiscella, C. P. Webb, M. Anver, S. Koochekpour, and G. F. Vande Woude. Mutationally activated Met receptor mediates motility and metastasis. *Proc. Natl. Acad. Sci. U.S.A.* 95:14417-14422 (1998).
 40. B. Falini, B. Bigerna, M. Fizzotti, J. Oyckfirdm, S. A. Pileri, G. Delsol, A. Cargone, M. Paulli, U. Magrini, F. Menestrina, R. Giardini, S. Pilotti, A. Mezzelani, B. Ugolini, M. Billi, A. Pucciarini, R. Pacini, P. G. Pelicci, and L. Flenghi. ALK expression defines a distinct group of T/null cell lymphomas ("ALK lymphomas") with a wide morphological spectrum. *Am. J. Pathol.* 153:875-886 (1998).
 41. D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit. Rev. Oncol. Hematol.* 19:183-232 (1995).
 42. J. R. Woodburn. The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol. Ther.* 82:241-250 (1999).
 43. J. Baselga, P. LoRusso, R. Herbst, D. Rischin, M. Ranson, A. M. Maddox, and S. Averbuch. A pharmacokinetic/pharmacodynamic trial of ZD1839 (IRESSA™), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment). *Clin. Cancer Res.* 5(suppl):3735S (1999).
 44. M. Kris, M. Ranson, and D. Ferry. Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. *Clin. Cancer Res.* 5(suppl):3749S (1999).
 45. J. E. Darnell, Jr. STATs and gene regulation. *Science* 277:1630-1635 (1997).
 46. C. Schinder and J. E. Darnell, Jr. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. *Annu. Rev. Biochem.* 64:621-651 (1995).
 47. Z. Ni, W. Lou, L. S. Leman, and A. C. Gao. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. *Cancer Res.* 60:1225-1228 (2000).
 48. W. Lou, Z. Ni, K. Dyer, D. J. Tweardy, and A. C. Gao. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat 3 signaling pathway. *Prostate* 42:239-242 (2000).
 49. C. W. Anderson and T. H. Carter. DNA damage and the DNA-activated protein kinase-DNA-PK. *Curr. Top. Microbiol. Immunol.* 217:91-111 (1996).
 50. G. C. M. Smith and S. P. Jackson. The DNA-dependent protein kinase. *Genes Dev.* 13:916-934 (1999).
 51. K. K. Leuther, O. Hammarsten, R. D. Kornberg, and G. Chu. Structure of DNA-dependent protein kinase: Implications for the regulation by DNA. *EMBO J.* 18:1114-1123 (1999).
 52. S. J. DiBiase, Z.-C. Zeng, R. Chen, T. Hyslop, W. J. Curran, Jr., and G. Iliakis. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. *Cancer Res.* 60:1245-1253 (2000).
 53. P. A. Jeggo. DNA breakage and repair. *Adv. Genet.* 38:186-218 (1998).
 54. U. Grawunder, D. Zimmer, P. Kulesza, and M. R. Lieber. Requirement for an interaction of XRCC4 with DNA ligase IV for wild type V(D)J recombination and DNA double-strand break repair in vivo. *J. Biol. Chem.* 273:24708-24714 (1998).
 55. P. Baumann and S. C. West. DNA end-joining catalyzed by human cell-free extracts. *Proc. Natl. Acad. Sci. USA* 95:14066-14070 (1998).
 56. D. Schwartz and V. Rotter. p53-dependent cell cycle control: Response to genotoxic stress. *Semin. Cancer Biol.* 8:325-336 (1998).
 57. A. M. Senderowicz. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. *Invest. New Drugs* 17:313-320 (1999).
 58. L. Yu, L. Orlandi, P. Wang, M. S. Orr, A. M. Senderowicz, E. A. Sausville, R. Silvestrini, N. Watanabe, H. Piwnicka-Worms, and P. M. O'Connor. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. *J. Biol. Chem.* 273:33455-33464 (1998).

59. V. C. Jordan. Antiestrogens: clinical applications of pharmacology. *J. Soc. Gynecol. Invest.* 7(Suppl):S47-S48 (2000).
60. R. J. Davis. MAPKs: New JNK expands the group. *Trends Biochem. Sci.* 19:470 (1994).
61. J. D. Graves and E. G. Krebs. Protein phosphorylation and signal transduction. *Pharmacol. Ther.* 82:111-121 (1999).
62. X. Hu, L. C. Mosciński, N. I. Valkov, A. B. Fisher, B. J. Hill, and K. S. Zuckerman. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. *Cell Growth Differ.* 11:191-200 (2000).
63. R. Das and B. K. Vonderhaar. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. *Breast Cancer Res. Treat.* 40:141 (1996).
64. A. Virkamäki, K. Ueki, and C. R. Kahn. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. *J. Clin. Invest.* 103:931-943 (1999).
65. J. P. Carson, G. Kulik, and M. J. Weber. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3-kinase and Akt/protein kinase B. *Cancer Res.* 59:1449-1453 (1999).
66. P. Sabbatini and F. McCormick. Phosphoinositide 3-OH kinase (PI3k) and PKB/Akt delay the onset of the p53-mediated, transcriptionally dependent apoptosis. *J. Biol. Chem.* 274:24263-24269 (1999).
67. R. Haq and B. Zanke. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. *Cancer Metastasis Rev.* 2:233-239 (1998).
68. A. Khwaja, F. Rodriguez-Viciana, S. Wennstrom, P. H. Warne, and J. Downward. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. *EMBO J.* 16:2783-2793 (1997).
69. G. Kulik, A. Klippel, and M. J. Weber. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. *Mol. Cell Biol.* 17:1595-1606 (1997).
70. G. W. Reuther and A. M. Pendergast. The roles of 14-3-3 proteins in signal transduction. *Vitam. Horm.* 52:149-175 (1996).
71. A. C. Newton. Protein kinase C: Structure, function, and regulation. *J. Biol. Chem.* 270:28495-28498 (1995).
72. D. Koya and G. L. King. Protein kinase C activation and the development of diabetic complications. *Diabetes* 47:859-966 (1998).
73. C. E. Chalfant, S. Ohno, Y. Konno, A. R. Fisher, L. D. Bisnath, J. E. Watson, and D. R. Cooper. A carboxy-terminal deletion mutant of protein kinase C β inhibits insulin-stimulated 2-deoxyglucose uptake in L6 rat skeletal muscle cells. *Mol. Endocrinol.* 10:1273-1281 (1996).
74. F. Shirakawa and S. B. Mizel. In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. *Mol. Cell Biol.* 9:2424-2430 (1989).
75. C. E. Chalfant, H. Mischak, J. E. Watson, B. C. Winkler, J. Goodnight, R. V. Farese, and D. R. Cooper. Regulation of alternative splicing of protein kinase C beta by insulin. *J. Biol. Chem.* 270:13326-13332 (1995).
76. Y. L. Siow, G. B. Kaimar, J. S. Sanghera, G. Tai, S. S. Oh, and S. L. Pelech. Identification of two essential phosphorylated threonine residues in the catalytic domain of Mek1. Indirect activation by Pak3 and protein kinase C. *J. Biol. Chem.* 272:7586-7594 (1997).
77. D. Perrotti, S. Bonatti, R. Trotta, R. Martinez, T. Skorski, P. Salomoni, E. Grassilli, R. V. Iozzo, D. R. Cooper, and B. Calabretta. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. *EMBO J.* 17:4442-4455 (1998).
78. D. R. Cooper, J. E. Watson, N. Patel, P. Illingworth, M. Acevedo-Duncan, J. Goodnight, C. E. Chalfant, and H. Mischak. Ectopic expression of protein kinase C β II, δ , and ϵ but not β I or ζ , provide for insulin stimulation of glucose uptake in NIH-3T3 cells. *Arch. Biochem. Biophys.* 372:69-79 (1999).
79. M. Kellerer, J. Mushack, E. Seffer, H. Mischak, A. Ulrich, and H. U. Haring. Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells). *Diabetologia* 41:833-838 (1998).
80. N. Y. Shih and G. Floyd-Smith. Protein kinase C-delta mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate. *J. Biol. Chem.* 271:16040-16046 (1996).
81. N. A. Patel, C. E. Chalfant, M. Yamamoto, J. E. Watson, D. C. Eichler, and D. R. Cooper. Acute hyperglycemia regulates transcription and post-transcriptional stability of PKC β II mRNA in vascular smooth muscle cells. *FASEB J.* 13:103-113 (1999).
82. E. G. Marcusson, B. R. Yacysbya, W. R. Shanshan, Jr., and N. M. Dean. Preclinical and clinical pharmacology of antisense oligonucleotides. *Mol. Biotechnol.* 12:1-11 (1999).
83. L. P. Aiello, S. Bursell, T. Devries, C. Alatorre, G. King, and K. W. W. Protein kinase C- β inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. *Diabetes* 48 (Suppl. 1):A19 (1999).
84. E. G. Krebs, D. J. Graves, and E. H. Fischer. Factors affecting the activity of muscle phosphorylase b kinase. *J. Biol. Chem.* 234:2867-2877 (1959).

APPENDIX 25



The anti-diarrheal agent loperamide sensitized MCF-7 clone 10.3 cells to the cytotoxic effect of doxorubicin as judged by the MTT assay for cell viability.

[Back](#)


Abstract Number: 2139

Evaluation of a series of 1,1-dichloro-2,3-di- and tri-arylcyclopropanes as MDR reversing agents

Yanfei Zhou, Rajagopalan Sridhar, Xinbin Gu, Xiaowu Pang, Raghavan Balachandran, Robert A. Magarian, Billy W. Day. *Howard University, Washington, DC, University of Pittsburgh, Pittsburgh, PA, University of Oklahoma, Oklahoma City, OK.*

Multidrug resistance of tumor cells can be a problem in cancer therapy with drugs such as doxorubicin (Dox). It is known that the antiestrogen, tamoxifen sensitizes multidrug resistant human breast cancer cells to doxorubicin cytotoxicity. Tamoxifen is not a pure antiestrogen, since it can exhibit some estrogenic activity and increase the risk of endometrial tumors. The pure antiestrogen, Analog II (Z-1,1-dichloro-2,3-diphenylcyclopropane), which was found to be effective as a suppressor of DMBA-induced mammary tumors, was not effective in sensitizing doxorubicin resistant MCF-7/MDR clone 10.3 human breast cancer cells (obtained from M.M Gottesman, NCI). A series of 1,1-dichloro-2,3-di- and 2,2,3-tri-arylcyclopropanes, were evaluated against MCF-7/MDR clone 10.3 cells with respect to their potential for overcoming cellular resistance to doxorubicin. Single cell suspensions of MCF-7/MDR clone 10.3 cells were exposed to graded concentrations of doxorubicin alone and in combination with fourteen antiestrogens at 10 micro molar concentration for three days. Cell viability was assayed in triplicate samples, using the MTT assay and the IC_{50} values for doxorubicin alone and IC_{50} values for doxorubicin in the presence of the cyclopropanes were determined. Comparison of the IC_{50} values gave the extent of reversal of doxorubicin resistance at the 50% survival level. Data for eleven effective compounds are tabulated below (Table). Seven out of the eleven compounds were comparable to tamoxifen in terms of their ability to overcome multidrug resistance. Not listed in the table are Analog II and diethylstilbestrol (DES), which had no effect, as well as dienestrol, which caused 1.6 fold reversal of MDR. These cyclopropyl derivatives have the additional advantage of being pure antiestrogens that may not be associated with the risk of endometrial cancer.

Table: Tamoxifen and 1,1-dichloro-2,3-di- and tri- arylecyclopropanes as MDR reversing agents



| Test compound | R ¹ | R ² | R ³ | IC ₅₀ (μM) for Dox alone | IC ₅₀ (μM) for Dox in presence of test compound | Fold reversal of MDR |
|---------------|--|--|-------------------|-------------------------------------|--|----------------------|
| BDRM28 | -Ph | -OCH ₂ CH ₂ Br | -H | 53.0 | 10.0 | 5.3 |
| BDRM38 | -C ₆ H ₄ -4-OCH ₃ | -OCH ₂ Ph | -H | 53.0 | 17.5 | 3.0 |
| BDRM81 | -C ₆ H ₄ -4-OCH ₃ | -H | -H | 53.0 | 14.0 | 3.8 |
| BDRM64 | -C ₆ H ₄ -4-OCH ₃ | -OCH ₂ Ph | -OCH ₃ | 53.0 | 8.0 | 6.6 |
| BDRM72 | -Ph | -OCH ₃ | -H | 53.0 | 9.05 | 5.9 |
| BDRM81 | -Ph | -H | -H | 53.0 | 14.0 | 3.8 |
| BDRM83 | -Ph | -OCH ₂ CH ₂ Br | -OCH ₃ | 53.0 | 10.05 | 5.3 |
| BDRM85 | -H | -OCH ₂ CH ₂ N(CH ₃) ₂ | -H | 53.0 | 9.05 | 5.9 |
| BDRM86 | -H | -O(CH ₂) ₂ N-(CH ₂) ₄ -NH ₂ | -H | 53.0 | 10.05 | 5.3 |
| BDRM87 | -H | -O(CH ₂) ₂ N-(CH ₂) ₄ | -H | 53.0 | 9.0 | 5.9 |
| TAMOXIFEN | | | | 53.0 | 7.01 | 7.1 |

(Supported in part by grant #DAMD17-98-1-8109 from the Department of Defense and grant 2G12RR003048 from the RCMI program of NCCR, NIH.)

Presenter: Yanfei Zhou

Affiliation: Howard University, Washington, DC; E-mail: yzhou@howard.edu

Copyright © 2004 American Association for Cancer Research. All rights reserved. Citation information: Proceedings of the AACR, Volume 45, March 2004.

APPENDIX 27

Chemomodulation of multi-drug resistance of human
breast cancer cells *in vitro*.

Nicola Ally, Yanfei Zhou, Renshu Zhang and Rajagopalan Sridhar

Department of Radiation Oncology and Cancer Center, Howard University,

Washington, DC 20060

* Corresponding author. Tel: +1-202-865-4968; fax: +1-202-667-1686

25 pages including 10 figures and figure legends

Abstract:

Doxorubicin is a potent anticancer drug that is used for treating a wide range of neoplasms including breast cancer. The full clinical potential of this drug has not been attained because of its cardiotoxic side effects. The development of multidrug resistance in tumors can also minimize the efficacy of doxorubicin. One mechanism of multidrug resistance in tumors is associated with overproduction of a permeability glycoprotein *Pgp* that acts as an energy dependent transport pump. This glycoprotein pump facilitates the efflux of doxorubicin and a variety of structurally unrelated cancer drugs out of the cell. Cells that overexpress *Pgp* are refractory to conventional chemotherapy because they fail to accumulate and retain lethal concentrations of the anti-cancer drug. In this paper we compare two structurally related alkaloids berberine and tetrandrine for their ability to modify the sensitivity, and the cytotoxicity of doxorubicin towards MCF-7 clone 10.3 multidrug resistant human breast cancer cells in culture.

The institute for alternative medicine, NIH has identified these two alkaloids for evaluation as anticancer agents. Preliminary studies indicate that tetrandrine is superior to berberine in sensitizing multidrug resistant MCF-7 clone 10.3 cells towards doxorubicin. Tetrandrine was more cytotoxic than berberine even in the absence of doxorubicin. The profiles and shapes of the dose response curves were different for drug sensitive and drug resistant cells treated with graded doses of doxorubicin.

1. Introduction

Multidrug resistance of tumor cells can be a problem in cancer chemotherapy using doxorubicin (Adriamycin). Doxorubicin is cardiotoxic. For optimum use of doxorubicin, it is necessary to overcome tumor resistance to drug while preventing cardiotoxicity. Permeability glycoprotein (*Pgp*) is encoded by *mdr* family of genes. Cells with high levels of (*Pgp*) are refractory to doxorubicin treatment because they do not accumulate sufficient concentration of the drug. This transmembrane protein is an energy dependent efflux pump for a wide range of structurally diverse cytotoxic drugs. Overexpression of *mdr* genes is one of several mechanisms associated with multidrug resistance of tumors (1-5). Potent anti-cancer drugs such as doxorubicin, etoposide, paclitaxel and vincristine are among those affected by multidrug resistance (MDR).

There are several pre-clinical and clinical investigations of chemicals that inhibit *Pgp* and restore drug sensitivity in MDR cells and tumors. The calcium channel blocker verapamil and the anti-estrogen tamoxifen are chemomodulators that partially overcome MDR *in vitro* and *in vivo*.

Berberine is a major component of the medicinal herb *Coptidis rhizoma* (known as *oren* in Japan and *huanglian* in China) that has been used in Ayurvedic and Chinese medicine for treating a variety of diseases. The alkaloid tetrandrine, present in the root of *Stephania tetrandra*, has been used in Chinese medicine for the treatment of arthritis. Berberine and tetrandrine inhibit proliferation of cancer cells in culture. The mechanisms of action of these drugs are not clear. In this communication we are

comparing the two alkaloids as modifiers of doxorubicin resistance in multidrug resistant breast cancer cell line MCF-7 clone 10.3.

Cardiotoxicity of doxorubicin may arise from its tendency to accumulate in the heart and trigger free radical -mediated injury (6). Many synthetic and natural compounds have been tested for their ability to function as chemomodulators of MDR and decrease tumor resistance to doxorubicin. It is important to identify and avoid conditions under which the chemomodulator sensitizes the heart to the deleterious effects of doxorubicin. Free radicals are known to induce apoptosis. Therefore there is much interest in identifying compounds that sensitize multidrug resistant cells to doxorubicin while acting simultaneously to protect against drug associated cardiotoxicity.

2. Methods and Materials

2.1. Chemicals

Tetrandrine and berberine sulfate were purchased from Sigma Chemical Co. Tissue culture supplies and assay kits were purchased from Invitrogen, inc.

2.2. Cells

MCF-7 human breast cancer cells and its multidrug resistant variant MCF-7 clone 10.3 cells (7) were cultured and maintained as exponential monolayers in a humidified 5% carbon dioxide air atmosphere in a 37°C incubator. RPMI 1640 medium fortified with 10% fetal bovine serum, glutamine (2mM), sodium pyruvate (1 mM) and 100 units/ml each of penicillin and streptomycin.

Exponentially growing cultures of MCF-7 wild type, a human breast cancer cell line sensitive to doxorubicin, and MCF-7 clone 10.3, a multidrug resistant cell line that is resistant to doxorubicin were treated with doxorubicin alone and in combination with berberine sulfate and / or tetrandrine. Cell viability was determined using an assay based on a tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide; MTT] (8). The effects of various concentrations of berberine and tetrandrine on the two cell lines were studied. The effects of combined treatments with the alkaloids and doxorubicin on cell viability were analyzed.

3. Results

MCF-7 clone 10.3 cells were several fold resistant to doxorubicin compared to MCF-7 wild type cells (Fig. 1). The cytotoxicity of tetrandrine towards MCF-7 clone 10.3 cells and MCF-7 wild type cells are shown (Fig. 2). The differences in sensitivities of the two cell lines to tetrandrine is not as dramatic as those observed with respect to doxorubicin toxicity (see Fig. 1 for comparison). Berberine, on its own was toxic to MCF-7 wild type cells over the 10 to 80 μ M range. Adding 4 μ M tetrandrine to the different concentrations of berberine only slightly increased the cytotoxicity towards MCF-7 wild type cells. Tetrandrine at 2 μ M level did not affect the cytotoxicity of berberine towards MCF-7 cells. (Fig. 3).

Berberine was cytotoxic in the 10 to 80 μ M range towards multidrug resistant MCF-7 clone 10.3 cells. In the case of these resistant cells, the cytotoxicity of berberine was increased by the addition of 2 or 4 micromolar tetrandrine. (Fig. 4). Moreover, the wild type and multidrug resistant MCF-7 cells did not differ much in their sensitivity to

berberine. This again is in sharp contrast to the differences in the sensitivities of these cell lines to doxorubicin (see Fig. 1 for comparison).

The cytotoxicity of doxorubicin towards the wild type parental MCF-7 cell line was only slightly affected by the antiestrogen tamoxifen (10 μ M). The survival was drastically reduced when tetrandrine (10 or 20 μ M) was combined with doxorubicin (Fig. 5). The doses of tetrandrine used in this case were rather high, in view of the fact that tetrandrine is cytotoxic even in the absence of doxorubicin.

Similar experiments showed that berberine (10 or 20 μ M) decreased the cell survival in the case of MCF-7 wild type cells treated with graded concentrations of doxorubicin (Fig. 6). Combinations of tetrandrine and berberine also decreased the cell survival of MCF-7 cells treated with different concentrations of doxorubicin (Fig. 7). Rather high doses of tetrandrine were used in these experiments. The results reflect the dominant effect of tetrandrine at these doses.

Tamoxifen (10 μ M) clearly sensitized multidrug resistant MCF-7 clone 10.3 cells to doxorubicin. Tetrandrine (2.5 to 10 μ M range) decreased the cell survival of these multidrug resistant cells treated with graded doses of doxorubicin. Tetrandrine is relatively non toxic to these cells at 2.5 μ M. This low dose of tetrandrine was more effective than tamoxifen, which is an effective multidrug resistance reversing agent, in overcoming resistance to tamoxifen (Fig. 8).

Berberine (20 μ M and 40 μ M) did not influence the cytotoxicity of doxorubicin towards multidrug resistant cells. Berberine was ineffective in overcoming resistance to doxorubicin (Fig. 9). Combinations of berberine and tetrandrine in the presence of

doxorubicin was very toxic to multidrug resistant MCF-7 clone 10.3 cells (Fig. 10). In this case the cytotoxic effect of tetrandrine may be the dominant factor.

4. Discussion

There is considerable interest in the medicinal properties of berberine and tetrandrine (9,10). Recently, the National Institutes of Health has identified these natural products for further investigations as anti cancer agents. Berberine has been shown to inhibit cancer cell proliferation and inhibit DNA topoisomerases (11,12). Both these alkaloids appear to be substrates for ATP binding glycoproteins associated with multidrug resistance (13-17). There are isolated reports that berberine may alter the expression of proteins associated with drug resistance (14). Upregulation of genes associated with multidrug resistance has been reported in cancer cells treated with berberine (14, 15). Based on these reports, berberine should protect against doxorubicin toxicity towards multidrug resistant MCF-7 clone 10.3 cells. Our experiments indicate that berberine is not an effective chemosensitizer of multidrug resistant MCF-7 clone 10.3 cells.

Upregulation of proteins such as *Pgp*, will increase drug resistance, while down regulation of the same will decrease drug resistance.

The wild type and multidrug resistant MCF-7 cell lines showed a multifold difference in sensitivity to doxorubicin, but not to tetrandrine or berberine. Both berberine and tetrandrine were cytotoxic to both cell lines even in the absence of doxorubicin.

Berberine, which has been reported to upregulate the expression of proteins associated with drug resistance did not sensitize drug resistant cells to doxorubicin mediated cytotoxicity. Tetrandrine, in sharp contrast was effective in overcoming resistance to doxorubicin. The effect of tetrandrine was not antagonized by berberine.

Our results indicate that tetrandrine is an effective chemosensitizer of multidrug resistant MCF-7 clone 10.3 cells towards doxorubicin. This is in accord with recent reports on reversal of multidrug resistance in cancer cells by tetrandrine (16-18). In view of these interesting results, further work is needed to elucidate the mechanisms associated with the pharmacological effects of these alkaloids.

This study demonstrates that tetrandrine is an important chemosensitizer with respect to doxorubicin toxicity in MCF-7 breast cancer cells that express the MDR phenotype. To our knowledge, this is the first study to demonstrate that tetrandrine also potentiated doxorubicin cytotoxicity despite treatment with berberine. This is significant because berberine is an upregulator of *Pgp*.

Acknowledgments: This research was supported in part by grant number DAMD 17-98.1.8109 from United States Army Medical Research and Materiel Command and in part by RCMI grant NIH/NCRR 2G1RR003048-16-A1

References

1. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. *Cytotechnology* 1993; 12: 171-212.
2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci* 2000; 11: 265-83.
3. Volm M. Multidrug resistance and its reversal. *Anticancer Res* 1998; 18: 2905-17.
4. Damle B, Sridhar R, Desai PB. Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells. *Int J Cancer* 1994; 56: 113-18.
5. Desai PB, Duan J, Sridhar R, Damle BD. Reversal of doxorubicin resistance in multidrug resistant Melanoma cells *in vitro* and *in vivo* by dipyridamole. *Meth Find Exp Clin Pharmacol* 1997; 19: 231-9.
6. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai PB, Engineer FN. Effects of verapamil on the acute toxicity of doxorubicin *in vivo*. *J Natl Cancer Inst* 1992; 84: 1653-60.
7. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson RB. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. *J Natl Cancer Inst* 1992; 84: 1506-12.

8. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semi automated colorimetric assay: assessment of chemosensitivity testing. *Cancer Res* 1987; 47: 943-946.
9. Huang KC. *The Pharmacology of Chinese Herbs*, 2nd ed. New York: CRC Press; 1999.
10. Fang JH, Fang YH. Tetrandrine: pharmacology and clinical usefulness. *Chinese Pharmaceut.J* 1996; 31: 454-7.
11. Li XK, Motwani M, Tong W, Bornmann W, and Schwartz GK. Huanglian, A Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. *Mol Pharmacol* 2000;58:1287-93.
12. Kobayashi Y, Yamashita Y, Fujii N, Takaboshi K, Kawakami T, Kawamura M, Mizukami T, Nakano H. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. *Planta Med* 1995;61:414-8.
13. Pan QC, Tian H. Reversal of multidrug resistance by various principles from Chinese herbal medicine. *Chin Sci Bull* 1996; 41: 410-4, 1996.
14. Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of *mdr1* gene product and the responses of digestive track cancer cells to Paclitaxel. *Br. J. Cancer* 1999; 81: 416-22.
15. Lin HL, Liu TL, Lui WY, Chi CW. Up regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. *Cancer* 1999; 85: 1937- 42.

16. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X, Pan Q.
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. *Cancer Chemother Pharmacol* 2004; 53: 349-56.
17. Liu ZL, Hirano T, Tanaka S, Onda K, Oka K. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug resistant human T lymphoblastoid leukemia MOLT-4 cells. *J Pharm Pharmacol* 2003; 55: 1531-37.
18. Chen YJ. Potential role of tetrandrine in cancer therapy. *Acta Pharmacol Sin* 2002; 23(12):1102-6.

Figure Legends

Figure 1. Comparison of the cytotoxicity of doxorubicin towards MCF-7 wild type (lower curve) and multidrug resistant MCF-7 clone 10.3 cells (upper curve). Multiwell cluster plates were seeded with ten thousand cells per well and incubated overnight for attachment to the substratum and then treated with different concentrations of doxorubicin and cell viability was assayed 72 hours later using the MTT assay.

Figure 2. Comparison of the cytotoxicity of tetradrine towards MCF-7 wild type (lower curve) and multidrug resistant MCF-7 clone 10.3 cells (upper curve). Multiwell cluster plates were seeded with ten thousand cells per well and incubated overnight for attachment to the substratum and then treated with different concentrations of tetradrine and cell viability was assayed 72 hours later using the MTT assay

Figure 3. Cytotoxicity of berberine (BER) tetradrine combinations towards wild type MCF-7 cells. Attached cells in 96 multiwell plates were treated with different concentrations of berberine alone or in combination with tetradrine for 72 hours before processing for MTT assay for cell viability. Open circles – berberine alone ; solid squares – berberine with tetradrine (2 μ M) ; open triangles – berberine with tetradrine (4 μ M).

Figure 4. Cytotoxicity of berberine (BER) tetradrine combinations towards multidrug resistant MCF-7 clone 10.3 cells. Attached cells in 96 multiwell plates were treated with different concentrations of berberine alone or in combination with tetradrine for 72

hours before processing for MTT assay for cell viability. Open squares - berberine alone; solid triangles - berberine with tetrandrine (2 μ M); solid squares - berberine with tetrandrine (4 μ M)

Figure 5. The influence of tetrandrine and tamoxifen on the cytotoxicity of doxorubicin towards MCF-7 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of tetrandrine (TEN) or tamoxifen at the concentrations indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M) ; open triangles- doxorubicin with tetrandrine (10 μ M); cross (x) - doxorubicin with tetrandrine (20 μ M)

Figure 6. The influence of berberine and tamoxifen on the cytotoxicity of doxorubicin towards MCF-7 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of berberine (BER) or tamoxifen at the concentrations indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M) ; open circles- doxorubicin with berberine (10 μ M); cross (x) - doxorubicin with berberine (20 μ M)

Figure 7. The influence of berberine-tetrandrine combinations and tamoxifen on the cytotoxicity of doxorubicin towards MCF-7 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of berberine (BER) -tetrandrine (TEN) combinations or tamoxifen at the concentrations

indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M) ; open triangles- doxorubicin with berberine (10 μ M) plus tetrandrine (10 μ M); cross (x) - doxorubicin with berberine (20 μ M) plus tetrandrine (20 μ M)

Figure 8. The influence of tetrandrine and tamoxifen on the cytotoxicity of doxorubicin towards multidrug resistant MCF-7 clone 10.3 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of tetrandrine (TEN) or tamoxifen at the concentrations indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M) ; open squares – doxorubicin in the presence of tetrandrine (2.5 μ M) ; open triangles- doxorubicin with tetrandrine (5 μ M); cross (x) - doxorubicin with tetrandrine (10 μ M) ; open circles - doxorubicin with tetrandrine (20 μ M)

Figure 9. The influence of berberine and tamoxifen on the cytotoxicity of doxorubicin towards multidrug resistant MCF-7 clone 10.3 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of berberine (BER) or tamoxifen at the concentrations indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M) ; cross (x)- doxorubicin with berberine (20 μ M); open triangles - doxorubicin with berberine (40 μ M)

Figure 10. The influence of tamoxifen and combinations of tetrandrine and berberine on the cytotoxicity of doxorubicin towards multidrug resistant MCF-7 clone 10.3 cells. Cell viability was determined after 72 hour treatment with different concentrations of doxorubicin alone or in the presence of tamoxifen (10 μ M) or combinations of berberine and tetrandrine at the concentrations indicated in the legend. Solid diamonds- doxorubicin alone; solid squares- doxorubicin in the presence of tamoxifen (10 μ M); solid triangles - doxorubicin with berberine (10 μ M) plus tetrandrine (20 μ M); open circles - doxorubicin with berberine (10 μ M) plus tetrandrine (10 μ M)




Fig. 1




Fig. 2




Fig. 3

Wild




Fig. 4
Resistant




Fig. 5

Wild




Fig. 6

Wild




Fig. 7

Wild




Figure 8

Resistant




Fig. 9

Resistant




Fig. 10
Resistant

FASEB J. 13: A920, 1999. Abstract #682.14 presented at "EXPERIMENTAL BIOLOGY 99", Washington, DC April 17-21, 1999.

A920

CARCINOGENESIS—OTHER DIETARY COMPONENTS (602.11-682.14)

TUESDAY AM

682.14

MCF-7 AND MCF-7/ADR CELLS RESPOND DIFFERENTLY TO CHANGES IN GLUCOSE CONCENTRATIONS. R. Kessler, M. Yassin, N.A. Patel and D.R. Conner, Howard Univ. Hospital and Cancer Center, Washington, DC 20059 and Univ. of South Florida College of Medicine and J.A. Haley Veterans Hospital, Tampa, FL 33611.

Glucose is a major source of energy in tumor cells and diabetes may be a risk factor for breast cancer and endometrial cancer. The human breast cancer cell line MCF-7 and its multidrug resistant variant MCF-7/ADR differ in their response to changes in glucose concentrations in the culture medium. A shift of glucose concentration from normal (5.5 mM) to high (25.8 mM) levels caused an increase in DNA synthesis and proliferation of MCF-7 cells but not MCF-7/ADR cells in monolayer cultures. High glucose induced decrease in PKC- β protein and mRNA levels during DNA synthesis phase in MCF-7 cells but not in MCF-7/ADR cells. The levels of protein kinase C- β (PKC- β) protein and the corresponding mRNA levels were 2 to 4 fold higher in MCF-7/ADR cells compared to MCF-7 cells, but were not down regulated by high glucose. These results indicate a possible role of PKC- β in down regulation in the acceleration of the cell cycle in MCF-7 cells cultured in medium containing high glucose concentrations.

Supported by USAMRAA grant DAMD 17-98-1-1109 (RSC), Department of Veterans Affairs and NCI MCB-9721955 (DRC) and Veterans Memorial Foundation (MY).